<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Finasteride</title><meta name="description" content="Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Propecia, Proscar"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Finasteride"/><meta property="og:title" content="Finasteride"/><meta property="og:description" content="Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed..."/><meta property="og:url" content="https://grokipedia.com/page/Finasteride"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Finasteride"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.517Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Finasteride"/><meta name="twitter:description" content="Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="d664c2b1abeb0f9ff0c0cd1aa252d3f2-2de78f3ab8bc272a-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=d664c2b1abeb0f9ff0c0cd1aa252d3f2,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.5882461983810146,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#finasteride" class="transition-opacity hover:opacity-100 opacity-50">Finasteride</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacodynamics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacodynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-indications" class="transition-opacity hover:opacity-100 opacity-50">Clinical Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#benign-prostatic-hyperplasia" class="transition-opacity hover:opacity-100 opacity-50">Benign Prostatic Hyperplasia</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#androgenetic-alopecia" class="transition-opacity hover:opacity-100 opacity-50">Androgenetic Alopecia</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hirsutism-and-other-uses" class="transition-opacity hover:opacity-100 opacity-50">Hirsutism and Other Uses</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#efficacy-evidence" class="transition-opacity hover:opacity-100 opacity-50">Efficacy Evidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#studies-on-bph" class="transition-opacity hover:opacity-100 opacity-50">Studies on BPH</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#studies-on-hair-loss" class="transition-opacity hover:opacity-100 opacity-50">Studies on Hair Loss</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Outcomes</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Adverse Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#sexual-side-effects" class="transition-opacity hover:opacity-100 opacity-50">Sexual Side Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#neuropsychiatric-effects" class="transition-opacity hover:opacity-100 opacity-50">Neuropsychiatric Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other-physical-effects" class="transition-opacity hover:opacity-100 opacity-50">Other Physical Effects</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-finasteride-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Post-Finasteride Syndrome</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#reported-symptoms-and-prevalence" class="transition-opacity hover:opacity-100 opacity-50">Reported Symptoms and Prevalence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#evidence-supporting-causality" class="transition-opacity hover:opacity-100 opacity-50">Evidence Supporting Causality</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#counterarguments-and-alternative-explanations" class="transition-opacity hover:opacity-100 opacity-50">Counterarguments and Alternative Explanations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-and-legal-responses" class="transition-opacity hover:opacity-100 opacity-50">Regulatory and Legal Responses</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#safety-profile-and-risk-benefit-analysis" class="transition-opacity hover:opacity-100 opacity-50">Safety Profile and Risk-Benefit Analysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dose-dependent-risks" class="transition-opacity hover:opacity-100 opacity-50">Dose-Dependent Risks</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#topical-vs-oral-formulations" class="transition-opacity hover:opacity-100 opacity-50">Topical vs. Oral Formulations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#interactions-and-overdose" class="transition-opacity hover:opacity-100 opacity-50">Interactions and Overdose</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history-and-development" class="transition-opacity hover:opacity-100 opacity-50">History and Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery-and-approval" class="transition-opacity hover:opacity-100 opacity-50">Discovery and Approval</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#key-clinical-trials" class="transition-opacity hover:opacity-100 opacity-50">Key Clinical Trials</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#evolution-of-indications" class="transition-opacity hover:opacity-100 opacity-50">Evolution of Indications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#society-and-culture" class="transition-opacity hover:opacity-100 opacity-50">Society and Culture</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#branding-generics-and-availability" class="transition-opacity hover:opacity-100 opacity-50">Branding, Generics, and Availability</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#use-in-athletics-and-doping" class="transition-opacity hover:opacity-100 opacity-50">Use in Athletics and Doping</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#public-perception-and-controversies" class="transition-opacity hover:opacity-100 opacity-50">Public Perception and Controversies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ongoing-research" class="transition-opacity hover:opacity-100 opacity-50">Ongoing Research</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recent-developments-2024-2025" class="transition-opacity hover:opacity-100 opacity-50">Recent Developments (2024-2025)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emerging-therapies-and-alternatives" class="transition-opacity hover:opacity-100 opacity-50">Emerging Therapies and Alternatives</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="finasteride" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Finasteride<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Developed by Merck &amp; Co., it received U.S. Food and Drug Administration (FDA) approval in 1992 at a 5 mg dose (Proscar) for BPH and in 1997 at a 1 mg dose (Propecia) for male pattern hair loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_140qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical trials demonstrate finasteride&#x27;s efficacy in reducing BPH progression and complications in men with enlarged prostates, with sustained improvements in urinary symptoms and flow rates over years of use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> For androgenetic alopecia, it increases hair count and prevents further loss in a majority of users, outperforming placebo in randomized studies, though benefits reverse upon discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite its therapeutic successes, finasteride is associated with adverse effects, including reduced libido, erectile dysfunction, and ejaculatory disorders, which occur in 1-5% of users and may persist beyond treatment cessation in a subset of cases, a condition termed post-finasteride syndrome (PFS).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Empirical evidence from patient reports, clinical observations, and small-scale studies supports the existence of persistent sexual, neurological, and psychological symptoms in some individuals, though large-scale causality remains debated due to challenges in study design and low incidence rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Long-term use also elevates risks of high-grade prostate cancer detection in some analyses, prompting updated FDA warnings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_101qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> These risks underscore the need for informed consent, particularly given DHT&#x27;s role in male physiology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_181qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pharmacodynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacodynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride functions as a selective, competitive inhibitor of the type II isoenzyme of steroid 5α-reductase, an NADPH-dependent enzyme that catalyzes the irreversible reduction of testosterone to dihydrotestosterone (DHT) at the Δ4-3-keto position of the steroid A ring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This inhibition disrupts the primary biochemical pathway for DHT biosynthesis, which exhibits approximately threefold higher potency than testosterone in binding to the androgen receptor due to its reduced affinity for sex hormone-binding globulin and enhanced transcriptional activation in target tissues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> The binding of finasteride to the enzyme&#x27;s active site forms a stable enzyme-inhibitor complex, preventing substrate access and thereby reducing DHT production without directly affecting testosterone synthesis or other upstream steroidogenic enzymes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In systemic circulation, daily oral dosing of 5 mg finasteride achieves approximately 65-70% suppression of serum DHT levels within 24 hours, stabilizing at this reduction with continued administration, while prostate tissue DHT concentrations decline by 80-90% due to the predominance of type II 5α-reductase expression in prostatic epithelium and stroma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Scalp dermal papilla cells, also enriched in type II isoenzyme, experience comparable localized DHT depletion of 60-70%, contrasting with minimal alterations in serum testosterone, which may rise modestly (8-15%) as a compensatory feedback from reduced metabolic clearance to DHT.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> This tissue-specificity arises from differential isoenzyme distribution—type II prevailing in genital skin, prostate, and hair follicles—allowing finasteride to attenuate DHT-dependent androgen signaling in these sites without broadly impairing testosterone-mediated pathways elsewhere.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Initial enzyme blockade preserves levels of unconverted androgens and type I 5α-reductase substrates, but sustained inhibition can indirectly perturb downstream cascades, including potential reductions in neuroactive steroids derived from progesterone and deoxycorticosterone via 5α-reduction in the central nervous system, where type II activity contributes modestly alongside type I.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Such alterations may modulate GABA_A receptor allosteric function through decreased allopregnanolone, influencing neuronal excitability, though the net impact on androgen receptor hypersensitivity or epigenetic adaptations in DHT-sensitive tissues remains under investigation and tied to duration of exposure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Long-term pharmacodynamic modeling indicates near-complete saturation of type II inhibition at standard doses, with dose-independent plateauing of DHT suppression beyond 1-5 mg daily.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="pharmacokinetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is rapidly absorbed following oral administration, with an absolute bioavailability of approximately 65% that is unaffected by concomitant food intake. Peak plasma concentrations occur within 1 to 2 hours after dosing. Steady-state plasma levels are achieved after approximately 3 days of daily dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The apparent volume of distribution at steady state averages 76 liters (range 44-96 liters). Circulating finasteride is approximately 90% bound to plasma proteins. Finasteride distributes into semen, where concentrations average 1.5-fold higher than simultaneous serum levels, though the total amount per ejaculate represents less than 0.001% of the daily dose.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride undergoes extensive first-pass hepatic metabolism, primarily via cytochrome P450 3A4, to pharmacologically inactive metabolites including monocarboxylic acid and glucuronide conjugates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The terminal elimination half-life averages 5-6 hours (range 3-16 hours) in younger men (aged 18-60 years) and approximately 8 hours (range 6-15 hours) in elderly men over 70 years, reflecting modestly reduced clearance with age. Nonlinear pharmacokinetics occur due to saturable binding to 5α-reductase; thus, steady-state plasma concentrations after 1 mg daily (mean ~9 ng/mL) are disproportionately lower relative to those after 5 mg daily (mean ~37 ng/mL). Excretion is predominantly fecal (57%, range 51-64%) with the remainder urinary (39%, range 32-46%), almost entirely as metabolites. Less than 0.1% of the dose is recovered unchanged in urine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="clinical-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="benign-prostatic-hyperplasia" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Benign Prostatic Hyperplasia<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate, where it reduces prostate volume and thereby alleviates associated lower urinary tract symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> By selectively inhibiting the type II isoform of 5α-reductase, the enzyme that converts testosterone to the more potent androgen dihydrotestosterone (DHT), finasteride lowers serum DHT levels by approximately 70% and intraprostatic DHT by 80-90%, promoting apoptosis of prostate epithelial cells and inhibiting further glandular hyperplasia driven by androgen signaling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This DHT suppression targets the underlying pathophysiology of BPH, where elevated local DHT concentrations contribute to prostate enlargement beyond 30-40 grams in volume.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The standard therapeutic dose for BPH is 5 mg administered orally once daily, with full effects on prostate size and symptom improvement generally requiring 6-12 months of continuous treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Prostate volume typically decreases by 18-20% after 12 months of 5 mg daily therapy, facilitating reduced urethral compression and enhanced bladder emptying.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This volume reduction correlates with improvements in urinary flow dynamics, including increased maximum urinary flow rates and decreased post-void residual urine volumes, which help mitigate obstructive symptoms such as hesitancy, weak stream, and incomplete voiding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Additionally, by shrinking the prostate, finasteride lowers the likelihood of acute urinary retention, a common BPH complication necessitating catheterization or surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In cases of moderate-to-severe symptomatic BPH, particularly with prostates larger than 40 grams, combination therapy pairing finasteride with an alpha-1 adrenergic blocker (e.g., doxazosin at up to 8 mg daily) is often employed to achieve synergistic effects: the 5α-reductase inhibitor addresses static obstruction from prostate enlargement, while the alpha-blocker rapidly relaxes prostatic smooth muscle to relieve dynamic components of outflow resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> This approach is supported by clinical guidelines for patients at higher risk of disease progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<h3 id="androgenetic-alopecia" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Androgenetic Alopecia<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is approved by the U.S. Food and Drug Administration for the treatment of androgenetic alopecia in men, utilizing a 1 mg daily oral dose to address progressive hair follicle miniaturization driven by dihydrotestosterone (DHT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> This regimen, marketed as Propecia since its approval on December 19, 1997, focuses on men experiencing vertex and anterior mid-scalp pattern hair loss, excluding those with frontal baldness or receding hairline at the temples.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> The therapy requires ongoing use, as benefits diminish upon cessation, with hair counts reverting to baseline within approximately one year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The mechanism involves competitive inhibition of type II 5α-reductase, the enzyme primarily expressed in scalp hair follicles that converts testosterone to DHT, thereby reducing scalp DHT concentrations by 60-70%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> This targeted DHT suppression interrupts the androgen-dependent shortening of the anagen phase and follicle shrinkage characteristic of androgenetic alopecia, without fully eliminating DHT production or halting loss entirely.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Doses as low as 0.2 mg daily have shown DHT-lowering effects, but 1 mg optimizes scalp-specific inhibition while minimizing systemic impact compared to the 5 mg dose for benign prostatic hyperplasia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Use in women remains unapproved due to limited efficacy data and teratogenic risks, as finasteride can induce genital abnormalities in male fetuses via DHT suppression during critical developmental windows.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> It is contraindicated in pregnant or potentially pregnant women, with off-label application restricted to postmenopausal cases under specialist oversight, where small studies report variable hair density improvements but insufficient large-scale validation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Systemic exposure must be avoided, prompting exploration of topical formulations to mitigate fetal risks, though oral use demands strict contraception in premenopausal patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<h3 id="hirsutism-and-other-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Hirsutism and Other Uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is employed off-label for treating hirsutism in premenopausal women, particularly those with polycystic ovary syndrome (PCOS), at dosages typically ranging from 2.5 to 5 mg daily or intermittently to suppress dihydrotestosterone (DHT) levels and reduce androgen-dependent hair growth.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> Randomized trials have demonstrated reductions in Ferriman-Gallwey hirsutism scores by 31-34% and hair shaft diameter by 27-34% after 6-12 months of treatment, with efficacy comparable to anti-androgens like spironolactone or flutamide when used as monotherapy or adjunctively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ocqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Systematic reviews confirm improvements over placebo, especially beyond six months, though benefits are modest and require ongoing use to maintain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Evidence for finasteride&#x27;s role in hirsutism remains limited by small sample sizes in available randomized controlled trials (often n&lt;100) and a lack of large-scale, long-term studies assessing sustained efficacy or comparative superiority over established therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Side effects reported include dry skin, decreased libido, and headache, with higher incidence at 5 mg doses, though overall tolerability is favorable in short-term data; postmenopausal use shows similar patterns but with even sparser evidence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Investigational applications extend to conditions involving androgen excess, such as acne and seborrhea within seborrhea-acne-hirsutism-alopecia (SAHA) syndrome, where low-dose finasteride (e.g., 2.5 mg/day) has shown preliminary hair regrowth and symptom reduction in case series, but randomized data are absent.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> In transgender care, finasteride is explored off-label for mitigating androgenetic alopecia in transgender men on testosterone therapy, with case series reporting efficacy rates akin to cisgender males (up to 87% stabilization or regrowth at 1 mg/day), though without interference to masculinization; use in transfeminine individuals for hair preservation alongside estrogen lacks robust trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> These roles highlight empirical gaps, relying on non-randomized or small-cohort evidence rather than definitive clinical validation.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is contraindicated in women who are pregnant or may become pregnant due to its potential to cause abnormal external genitalia development, such as hypospadias, in male fetuses via 5α-reductase inhibition during critical embryogenesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Animal studies and mechanistic data underpin this risk, classifying it as pregnancy category X, with even topical exposure or handling of crushed tablets advised against; no human epidemiological excess has been confirmed for paternal preconception use, but maternal administration poses direct teratogenic threat.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_keabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<h2 id="efficacy-evidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Efficacy Evidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="studies-on-bph" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Studies on BPH<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Medical Therapy of Prostatic Symptoms (MTOPS) trial, a multicenter randomized controlled trial enrolling 3047 men with moderate to severe benign prostatic hyperplasia (BPH) symptoms, found that finasteride at 5 mg daily reduced the overall risk of clinical progression by 34% compared to placebo over a median follow-up of 4.8 years (hazard ratio 0.66; 95% CI 0.53-0.81).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Clinical progression was a composite endpoint including a ≥4-point worsening in American Urological Association Symptom Score (AUAss), acute urinary retention, urinary tract infection, incontinence, or need for invasive therapy. Finasteride monotherapy also improved peak urinary flow rate by 1.6 mL/s and reduced prostate volume by approximately 18% relative to placebo, with benefits accumulating over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Meta-analyses of randomized controlled trials (RCTs) have corroborated these findings, showing finasteride yields modest but statistically significant improvements in International Prostate Symptom Score (IPSS) of 2-4 points greater than placebo after 6-12 months, with effects sustained in long-term follow-up.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> Symptom relief with finasteride exhibits a delayed onset, typically requiring 3-6 months for noticeable IPSS reductions, in contrast to alpha-blockers which provide faster symptomatic improvement within weeks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ogabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> Peak flow rate improvements average 1-2 mL/s over placebo, primarily driven by prostate volume reduction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Subgroup analyses indicate finasteride&#x27;s benefits are most pronounced in men with larger prostates (≥40 mL or &gt;40 g), where RCTs and meta-analyses report significant reductions in symptom progression risk and IPSS (e.g., 3-5 point improvements) compared to placebo, whereas minimal effects occur in those with smaller glands (&lt;40 mL).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> In the MTOPS cohort, approximately half of participants had baseline prostate volumes ≥30 mL, aligning with enhanced efficacy in this subset, though overall progression risk reduction held across the trial population.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ogqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> Long-term data from trials like MTOPS and the Proscar Long-term Efficacy and Safety Study (PLESS) confirm sustained reductions in BPH progression and surgical interventions over 4-6 years in eligible patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<h3 id="studies-on-hair-loss" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Studies on Hair Loss<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The pivotal randomized controlled trials supporting finasteride&#x27;s approval for androgenetic alopecia involved two 12-month studies of 1 mg daily in men aged 18-41 with mild-to-moderate vertex hair loss, demonstrating a mean increase of 91 hairs per 1 cm² area compared to a loss of 19 hairs in the placebo group.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> These trials, published in 1998, reported that 48% of finasteride-treated men experienced visible improvement in hair growth versus 7% in the placebo group who showed no further progression of loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ghqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> A concurrent 1-year study on frontal scalp regions yielded similar results, with finasteride yielding a net hair count gain of approximately 10-15% over baseline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term extensions of these trials, extending to 5 years in over 500 men, confirmed durable scalp hair improvements, with mean hair counts stabilizing or modestly increasing beyond year 2 but plateauing thereafter, indicating maintenance rather than progressive gains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> In these open-label phases, 65% of participants maintained or improved hair growth at year 5 compared to baseline, versus expected progression in untreated cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> Meta-analyses of randomized trials affirm finasteride&#x27;s modest superiority over placebo, with standardized mean differences in hair density favoring treatment by 0.5-1.0 hairs per follicle, though effect sizes diminish after initial response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Data on women remain limited to small randomized controlled trials, often using doses of 1-5 mg daily in postmenopausal or normoandrogenic patients with female pattern hair loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> These studies report response rates of 30-50% for increased hair density or halted progression after 6-12 months, but with high variability and smaller sample sizes (n&lt;100 per arm) limiting generalizability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> A meta-analysis of such trials found statistically significant but clinically modest improvements in hair counts, though efficacy appears lower than in men and inconsistent across subgroups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<h3 id="long-term-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the Proscar Long-term Efficacy and Safety Study (PLESS), a 4-year randomized, placebo-controlled trial involving 3,040 men with benign prostatic hyperplasia (BPH), finasteride 5 mg daily produced sustained reductions in prostate volume by approximately 18-20% relative to baseline, alongside improvements in urinary symptom scores and maximum flow rates that persisted through the study duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> The risk of acute urinary retention (AUR) decreased by 57% in the finasteride group (2.8% incidence) compared to placebo (6.6%), with similar durability in reducing the combined risk of AUR or BPH-related invasive therapy by about 55%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> These benefits were most pronounced in men with baseline prostate volumes greater than 40 mL and PSA levels above 1.4 ng/mL, indicating progressive disease stabilization over extended treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ojqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For androgenetic alopecia, long-term observational data from a 10-year study of 523 Japanese men treated with finasteride 1 mg daily demonstrated persistent improvements in hair count and subjective assessments, with over 90% of participants maintaining or achieving moderate-to-marked efficacy by global photographic evaluation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> However, discontinuation typically results in reversal of gains, with hair density regressing to pretreatment levels or worse within 6-12 months due to resumption of dihydrotestosterone-driven follicular miniaturization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Five-year controlled trials similarly confirmed durable scalp hair growth while on therapy, but emphasized the necessity of indefinite use to prevent rebound progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_okabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Prostate Cancer Prevention Trial (PCPT), a 7-year study of finasteride 5 mg in 18,882 healthy men aged 55 and older, reported a 25% relative reduction in overall prostate cancer prevalence (18.4% in finasteride arm vs. 24.4% placebo), with 18-year follow-up data affirming sustained risk mitigation without excess mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Initial concerns of increased high-grade (Gleason 7-10) tumors (relative risk 1.27) were attributed to detection bias from finasteride&#x27;s prostate shrinkage and PSA effects rather than true promotion, as subsequent analyses showed no elevation in high-grade risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Across indications, the number needed to treat (NNT) for clinically meaningful BPH progression avoidance approximates 14 over 4 years, though benefits must be weighed against prolonged exposure in individual risk profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_okqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Adverse Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="sexual-side-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Sexual Side Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride, a 5α-reductase inhibitor, is associated with sexual side effects including erectile dysfunction (ED), decreased libido, and ejaculation disorders, primarily due to its suppression of dihydrotestosterone (DHT) levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> A 2019 systematic review and meta-analysis of 15 randomized controlled trials involving 4,495 men treated for androgenetic alopecia (typically with 1 mg/day finasteride) found a relative risk (RR) of 1.66 (95% CI: 1.20–2.30) for overall sexual dysfunction compared to placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Absolute incidence rates for these effects at 1 mg/day are low, typically 2–4% above placebo levels, with ED reported in approximately 1.3–1.7% of users in long-term studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_omabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">At higher doses used for benign prostatic hyperplasia (5 mg/day), the incidence is elevated. Meta-analyses indicate odds ratios (OR) for ED of 1.47–1.55 (95% CI: 1.14–2.12) and for decreased libido of 1.54 (95% CI: 1.29–1.82) in this context.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> Reported rates can reach 8–15% for sexual adverse events, compared to 2–4% at 1 mg/day, reflecting dose-dependent DHT suppression (70–80% reduction overall, but more pronounced effects on genital tissues at higher doses).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> In most cases, these effects are reversible upon discontinuation, though a subset experiences partial or delayed resolution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_omqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The mechanism involves DHT&#x27;s role in penile androgen signaling and nitric oxide (NO) production. DHT exhibits higher affinity for androgen receptors than testosterone and more potently upregulates endothelial NO synthase in the corpus cavernosum, facilitating vascular smooth muscle relaxation essential for erection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> Finasteride-induced DHT reduction impairs this pathway, decreasing NO bioavailability and promoting oxidative stress, which further disrupts erectile function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<h3 id="neuropsychiatric-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Neuropsychiatric Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride has been associated with neuropsychiatric adverse effects, including depression, anxiety, and suicidal ideation, primarily observed in pharmacovigilance databases and post-marketing reports. Analysis of the WHO VigiBase database identified 395 reports of suicidality and 1,299 reports of depression linked to finasteride use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> These effects are thought to arise from the drug&#x27;s inhibition of 5α-reductase, which reduces levels of neuroactive steroids such as allopregnanolone, a positive allosteric modulator of GABA_A receptors that promotes anxiolytic and antidepressant effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> Reduced allopregnanolone impairs GABAergic inhibition, potentially leading to mood dysregulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pharmacovigilance data indicate an upward trend in reported depression and suicidality signals, with a sharp rise in suicidality reports noted in 2024, despite some decline in reporting odds ratios from prior peaks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> The European Medicines Agency&#x27;s Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets in May 2025, based on disproportionate reporting primarily among users of the 1 mg dose for androgenetic alopecia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> This acknowledgment followed evaluation of global adverse event data, emphasizing the need for patient monitoring and risk minimization measures, such as informing users of potential mood changes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Younger male users, particularly those under 45 years old treated for hair loss, exhibit a higher relative risk for these effects compared to older populations or those using finasteride for benign prostatic hyperplasia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> Studies from databases like FAERS have reported three-fold increased likelihood of suicidal ideation or attempts in this demographic, attributed to greater vulnerability to neurosteroid disruptions during peak androgen sensitivity periods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup> Empirical evidence from signal detection supports mood-related symptoms like depression and anxiety occurring more frequently in this group, prompting recommendations for baseline psychiatric screening in younger patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<h3 id="other-physical-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Other Physical Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride treatment has been associated with gynecomastia in clinical trials, attributed to an imbalance in the testosterone-to-estradiol ratio resulting from inhibited dihydrotestosterone synthesis and relatively increased aromatization of testosterone to estradiol. In a meta-analysis of 14 studies on 5-alpha reductase inhibitors including finasteride for benign prostatic hyperplasia, gynecomastia occurred in 3.30% of treated patients compared to 1.62% on placebo, yielding an odds ratio of 2.15. For the 1 mg dose used in androgenetic alopecia, incidence is lower, with rates around 0.4% in long-term trials, though case reports document occurrences even after short-term low-dose exposure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Reports of male breast cancer during finasteride therapy are rare but have prompted debate on causality. Up to 2014, approximately 50 cases were reported worldwide with the 5 mg dose and three with 1 mg, against a background rate of male breast cancer of about 1 per 100,000 men annually. A population-based study found a 44% increased risk among finasteride users, potentially linked to hormonal shifts favoring estrogenic effects, though a large case-control analysis reported no material association after confounder adjustment. Regulatory bodies, including the UK&#x27;s MHRA, have noted the potential risk but emphasize its infrequency, with no definitive causal link established in controlled trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride reduces serum prostate-specific antigen (PSA) levels by approximately 50% within the first 12 months of treatment, necessitating a doubling of measured PSA values for accurate prostate cancer screening to avoid false negatives. This effect persists with continued use and enhances PSA&#x27;s specificity for detecting high-grade cancers, as observed in the Prostate Cancer Prevention Trial. No consistent evidence links finasteride to adverse metabolic changes, such as insulin resistance or dyslipidemia, or increased cardiovascular events in large cohorts; meta-analyses and trial data show neutral or potentially protective cardiac outcomes in some subgroups, though long-term risks like non-alcoholic fatty liver disease remain under investigation without conclusive signals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Dermatological reactions, including rash and urticaria, occur in less than 1% of users and are typically mild and reversible upon discontinuation. Case reports describe maculopapular eruptions, psoriasiform reactions, or urticarial rashes emerging weeks to months after initiation, often resolving after drug withdrawal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup></span>
<h2 id="post-finasteride-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Post-Finasteride Syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="reported-symptoms-and-prevalence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Reported Symptoms and Prevalence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Patients who report post-finasteride syndrome (PFS) describe a cluster of persistent symptoms emerging during finasteride use and enduring for more than three months after discontinuation, including sexual dysfunction such as erectile dysfunction (ED), reduced libido, and orgasmic impairment; neuropsychiatric effects like depression, anxiety, cognitive fog, and memory issues; and physical complaints encompassing chronic fatigue, muscle weakness, and dry skin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> In self-selected cohorts of affected individuals, surveys indicate high rates of these symptoms, with 92-94% reporting low libido and ED, alongside 34-49% experiencing anxiety or depression post-discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_otabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical prevalence estimates from retrospective cohort studies suggest persistent sexual symptoms affect approximately 0.8-1.4% of finasteride users, with one analysis of 11,909 exposed men identifying 1.4% developing persistent ED.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> Self-report registries, such as those maintained by the Post-Finasteride Syndrome Foundation, document over 25,000 worldwide adverse reaction reports linked to finasteride, predominantly involving persistent sexual (e.g., 4,077 ED cases) and psychiatric disorders (e.g., 2,235 depression cases), though these represent voluntary submissions from millions of total users and may reflect selection bias toward severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_otqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Pharmacovigilance data highlight underreporting in official systems, potentially underestimating true incidence, particularly among younger men treated for hair loss who comprise a disproportionate share of reports.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms often manifest after cumulative exposure to low doses (e.g., 1 mg daily for androgenetic alopecia), without a defined threshold, and persist variably for months to years in affected individuals, as evidenced by clinical trial follow-ups and patient surveys where dysfunction continued despite cessation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> Prevalence appears elevated in hair loss treatment cohorts compared to benign prostatic hyperplasia users, possibly due to longer-term, lower-dose regimens or demographic factors like younger age.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<h3 id="evidence-supporting-causality" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Evidence Supporting Causality<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Animal studies have demonstrated that finasteride withdrawal leads to persistent reductions in neurosteroid levels, particularly allopregnanolone, which modulates GABA_A receptors and influences mood, anxiety, and neuroinflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> In a 2025 preclinical rat model, finasteride administration followed by withdrawal decreased hypothalamic allopregnanolone and induced neuroinflammation, with exogenous allopregnanolone treatment mitigating these effects, suggesting a direct causal link via disrupted neurosteroid signaling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Human data corroborate this, showing decreased cerebrospinal fluid allopregnanolone levels persisting after discontinuation in patients reporting PFS symptoms, independent of ongoing 5α-reductase inhibition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ovabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Epigenetic mechanisms provide further evidence of causality, as finasteride&#x27;s inhibition of 5α-reductase alters gene expression through histone modifications and DNA methylation, leading to sustained changes in androgen receptor signaling and neurosteroid pathways.32599-3/fulltext) A 2024 study on human Leydig cells exposed to finasteride revealed epigenetic modifications in dopaminergic pathways, with differential gene expression observed in PFS patients compared to controls, indicating drug-induced transcriptional reprogramming as a persistent driver of symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Adverse drug reaction databases highlight temporal associations supporting causality, with VigiBase reporting disproportionate increases in finasteride-linked suicidality and self-injurious behaviors; for instance, suicidal ideation rose 4.2% and suicide attempts 3.7% in recent analyses, exceeding expected rates for the drug class.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cohort investigations identify biomarkers correlating with persistent symptoms in 1-2% of users, including altered steroid profiles and gut microbiota dysbiosis post-withdrawal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> A 2025 cohort study using fMRI detected abnormal brain activity in emotion-regulation regions among PFS patients without prior psychiatric history, alongside persistent neurosteroid imbalances.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> Genetic factors, such as shorter CAG repeats in the androgen receptor gene, increase susceptibility to these persistent effects by enhancing receptor sensitivity to disrupted steroid environments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<h3 id="counterarguments-and-alternative-explanations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Counterarguments and Alternative Explanations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Critics of post-finasteride syndrome (PFS) causality emphasize the nocebo effect, wherein awareness of potential side effects generates or amplifies symptoms through negative expectations. Placebo-controlled trials of finasteride for androgenetic alopecia reported sexual adverse events at rates comparable to placebo (e.g., 1.8% vs. 1.3% for decreased libido in pivotal studies), indicating that expectation bias, rather than direct pharmacology, may drive perceived persistence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A 2024 review in <em>Translational Andrology and Urology</em> by Carson et al. argues that PFS lacks substantiation as a distinct entity, attributing reports to unproven mechanisms amid insufficient blinded, prospective evidence linking finasteride cessation to enduring symptoms; the authors highlight that randomized data show effects as &quot;minimal and fleeting&quot; for most users, challenging claims of irreversibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pre-existing vulnerabilities among finasteride users, particularly those pursuing treatment for cosmetic hair loss, may confound attributions to the drug; such individuals often exhibit elevated baseline risks for anxiety, depression, or sexual dissatisfaction, potentially amplifying subjective complaints unrelated to 5α-reductase inhibition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> A 2025 analysis reframes PFS symptoms as manifestations of selection bias in patient cohorts prone to psychological distress from appearance concerns, rather than novel drug-induced pathology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Methodological flaws in PFS literature, including reliance on self-selected online surveys from advocacy forums, inflate prevalence estimates by excluding asymptomatic users and lacking validated controls or objective biomarkers; these designs fail to differentiate drug effects from regression to baseline or unrelated comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In manufacturer-sponsored trials, sexual side effects resolved in over 95% of cases upon discontinuation, with long-term follow-up (up to 5 years) showing no excess persistence beyond placebo rates, supporting reversibility as the norm rather than exception.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory assessments align with skepticism: the U.S. FDA, in its June 2022 response to a citizen petition, denied requests for enhanced labeling or market withdrawal, concluding the submitted evidence failed to establish reasonable causality for persistent effects beyond known, transient risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup></span>
<h3 id="regulatory-and-legal-responses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Regulatory and Legal Responses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In April 2025, the U.S. Food and Drug Administration (FDA) issued an alert to health care providers, compounders, and consumers about potential serious risks from compounded topical finasteride products, which lack FDA-approved labeling and established safety profiles; this followed 32 adverse event reports submitted to the FDA Adverse Event Reporting System between 2019 and 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In May 2025, the European Medicines Agency&#x27;s Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as an adverse reaction to finasteride 1 mg and 5 mg tablets, primarily reported in users treating androgenetic alopecia; the committee recommended risk minimization measures, including updated product information to warn of psychiatric effects and enhanced patient monitoring, while noting most cases resolved upon discontinuation but acknowledging potential persistence in some instances.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Multiple class-action lawsuits have targeted Merck, the maker of Propecia (finasteride 1 mg), claiming the company underreported risks of post-finasteride syndrome, including persistent neuropsychiatric harms linked to suicides, despite post-marketing data suggesting higher incidence than clinical trials indicated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> In ongoing 2025 Propecia litigation, expert witness testimony estimated hundreds to thousands of suicides attributable to finasteride-induced effects, based on pharmacovigilance analyses and underreporting factors, highlighting tensions between regulatory assurances of rarity and aggregated patient reports exceeding expected baselines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> These cases, including a 2021 suit by the Post-Finasteride Syndrome Foundation against the FDA for alleged inaction on labeling petitions, underscore discrepancies where agency positions have lagged behind litigation-revealed evidence volumes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<h2 id="safety-profile-and-risk-benefit-analysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Safety Profile and Risk-Benefit Analysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="dose-dependent-risks" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dose-Dependent Risks<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The incidence of adverse effects from finasteride exhibits dose dependence, with higher absolute risks at the 5 mg daily dose used for benign prostatic hyperplasia compared to the 1 mg dose for androgenetic alopecia. In pivotal trials, sexual side effects such as erectile dysfunction occurred in 8.1% of men on 5 mg versus 3.7% on placebo, while for 1 mg, the rate was 1.8% versus 1.1% on placebo.  Relative risks for sexual dysfunction remain elevated across doses, though absolute event rates are lower at 1 mg due to reduced systemic DHT inhibition (approximately 65-70% scalp DHT reduction at 1 mg versus near-complete at 5 mg).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Meta-analyses from 2018 to 2023 confirm a dose-independent relative risk elevation for adverse sexual effects, with 5α-reductase inhibitors including finasteride associated with a 1.57-fold increased risk (95% CI 1.19–2.08) of any sexual dysfunction versus placebo, irrespective of indication. Subgroup analysis for finasteride 1 mg yielded a 1.66-fold risk (95% CI 1.20–2.30), driven primarily by erectile dysfunction and decreased libido, while 5 mg showed comparable relative but higher absolute risks in prostate trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duration of exposure contributes to risk scaling, with cumulative use exceeding 1 year linked to heightened odds of persistent effects post-discontinuation; in cohorts with mean exposure of 28 months, over 90% of those developing side effects lasting ≥3 months experienced continuation for years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> No established safe threshold exists, as even low-dose, short-term use reports rare persistence in sensitive individuals.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Individual factors modulate dose-dependent risks: younger age (&lt;40 years) correlates with greater persistence likelihood, potentially due to neurosteroid disruption during peak androgen sensitivity, while genetic variants in androgen receptor or steroid metabolism genes (e.g., SRD5A2 polymorphisms) may predispose subsets to amplified effects, suggesting pharmacogenomic screening for high-risk patients. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup></span>
<h3 id="topical-vs-oral-formulations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Topical vs. Oral Formulations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Topical finasteride formulations are promoted for reducing dihydrotestosterone (DHT) primarily at the scalp site of application, with proponents claiming minimized systemic exposure compared to oral administration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup> Clinical trials have demonstrated that topical finasteride achieves scalp DHT reductions of 68-75%, comparable to 62-72% with oral finasteride, while exhibiting lower plasma finasteride concentrations and serum DHT suppression (e.g., 34.5% reduction versus 55.6% for oral).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_laabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup> This localized targeting is intended to preserve efficacy against androgenetic alopecia while attenuating body-wide hormonal effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_taabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">However, systemic absorption occurs via transdermal routes, leading to detectable serum DHT changes and potential adverse events akin to oral use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> In April 2025, the U.S. Food and Drug Administration (FDA) issued an alert regarding compounded topical finasteride products, citing reports of serious risks including erectile dysfunction, depression, anxiety, suicidal ideation, and decreased libido—symptoms consistent with finasteride&#x27;s known profile despite topical delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> These events underscore bioavailability challenges, as skin absorption bypasses first-pass hepatic metabolism and varies with factors like formulation, application site, and individual skin permeability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_paqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Compounded topical preparations introduce additional risks from dosing inconsistencies and quality variability, lacking standardized manufacturing controls of approved oral forms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Pharmacokinetic analyses indicate that while average systemic exposure is reduced, inter-patient absorption differences can result in unintended elevations in circulating finasteride levels, potentially negating safety advantages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regarding post-finasteride syndrome (PFS), topical formulations show fewer adverse event signals resembling PFS compared to oral in pharmacovigilance data, but cases have been documented, and no controlled evidence confirms prevention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Long-term studies are absent, leaving causality and risk mitigation unestablished for persistent symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup></span>
<h3 id="interactions-and-overdose" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Interactions and Overdose<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is primarily metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system, and inhibitors of this enzyme, such as ketoconazole, can increase its plasma concentrations and prolong its half-life by reducing clearance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Inducers of CYP3A4, like rifampin, may decrease finasteride levels, though clinical significance remains limited based on available data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> No clinically meaningful interactions with food have been observed, as bioavailability is approximately 65% regardless of administration with or without meals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Concomitant use with testosterone replacement therapy warrants caution, as finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT), potentially altering androgen profiles, though studies indicate compatibility without prohibitive risks in monitored settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For prostate cancer screening, finasteride reduces serum prostate-specific antigen (PSA) levels by about 50% after 6–12 months of use, requiring clinicians to double observed PSA values to interpret results accurately and avoid under-detection of prostate abnormalities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Overdose with finasteride is rare and typically non-life-threatening due to its wide therapeutic index. In animal toxicity studies, the oral median lethal dose (LD50) in rats is approximately 418 mg/kg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Human data from single doses up to 400 mg and repeated doses of 80 mg daily for three months show no serious adverse effects, with any symptoms—such as transient increases in serum testosterone due to inhibited 5α-reductase activity—being reversible upon discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> No fatalities attributable to finasteride overdose have been documented, and management involves supportive care without specific antidotes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h2 id="history-and-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History and Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="discovery-and-approval" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Discovery and Approval<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride, a synthetic 4-azasteroid compound, was developed by Merck &amp; Co. in the 1980s as a selective inhibitor of type II 5α-reductase, an enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in androgen-dependent tissues such as the prostate. Initially pursued to address prostate disorders by reducing DHT-mediated prostate enlargement and associated urinary symptoms in benign prostatic hyperplasia (BPH), the drug&#x27;s development leveraged early research identifying 5α-reductase as a therapeutic target for such conditions. Merck patented finasteride in 1984, focusing on its potency and tissue selectivity to minimize off-target effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Food and Drug Administration (FDA) approved finasteride 5 mg tablets under the brand name Proscar on June 19, 1992, for the treatment of symptomatic BPH in men, marking the first regulatory milestone for a 5α-reductase inhibitor in this indication. This approval was based on clinical data demonstrating reductions in prostate volume and improvements in urinary flow rates. Similar authorizations followed in the European Union shortly thereafter, with national agencies granting marketing approval for Proscar equivalents in the early 1990s to manage BPH symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory expansion to hair loss occurred through serendipitous findings during BPH studies, where participants exhibited reduced scalp DHT levels and hair regrowth, prompting investigation of lower doses for androgenetic alopecia. The FDA approved finasteride 1 mg tablets as Propecia on December 19, 1997, specifically for male pattern baldness in men aged 18-41, supported by trials showing sustained hair count increases over two years. European approvals for the 1 mg formulation trailed slightly, occurring in 1998-1999 across member states.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup></span>
<h3 id="key-clinical-trials" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Key Clinical Trials<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The pivotal phase III clinical trials for finasteride in benign prostatic hyperplasia (BPH) were conducted in the early 1990s and formed the basis for its approval as Proscar at a 5 mg daily dose by the U.S. Food and Drug Administration in June 1992. A multicenter, double-blind, placebo-controlled study involving 3,040 men with symptomatic BPH demonstrated that 5 mg finasteride daily for 12 months significantly reduced prostate volume by approximately 19% compared to placebo, improved urinary flow rates by 1.6 mL/s, and alleviated obstructive symptoms, with these benefits persisting in long-term extensions up to four years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Prostate Cancer Prevention Trial (PCPT), a large-scale, randomized, double-blind, placebo-controlled study published in 2003, evaluated 5 mg finasteride daily in 18,882 men aged 55 or older with normal prostate-specific antigen (PSA) levels and digital rectal exams. Over seven years, finasteride reduced overall prostate cancer prevalence by 24.8% (803 cases in the finasteride group versus 1,147 in placebo), but an increased detection of high-grade (Gleason score 7-10) tumors raised concerns about potential promotion of aggressive disease, though subsequent analyses debated whether this reflected detection bias from prostate volume reduction rather than true carcinogenesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For androgenetic alopecia, dose-ranging randomized controlled trials (RCTs) in the 1990s established 1 mg daily as optimal, leading to approval as Propecia in December 1997. These studies, involving men aged 18-41 with mild to moderate vertex or frontal hair loss, showed that 1 mg finasteride increased scalp hair count by 10-15% over one year versus placebo, with maximal dihydrotestosterone suppression in scalp tissue at doses as low as 0.2 mg but superior efficacy at 1 mg for hair regrowth and halting progression over two years; higher doses like 5 mg offered no additional benefit for hair while risking greater systemic effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> Large-scale RCTs for female pattern hair loss were absent during this period, with early investigations limited to off-label use and smaller cohorts showing inconsistent results until the 2010s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<h3 id="evolution-of-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Evolution of Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride received initial U.S. Food and Drug Administration (FDA) approval in June 1992 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men, marketed as Proscar at a 5 mg daily dose to reduce prostate volume and alleviate urinary symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This indication stemmed from clinical trials demonstrating its inhibition of 5α-reductase, which lowers dihydrotestosterone levels and shrinks enlarged prostates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> By the mid-1990s, its application expanded to male androgenetic alopecia following Merck&#x27;s development of a 1 mg formulation.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In December 1997, the FDA approved finasteride at 1 mg daily (Propecia) specifically for male pattern hair loss, marking a shift toward dermatological use driven by pivotal trials showing sustained hair count increases over five years in 65% of treated men versus placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This lower-dose approval broadened accessibility, particularly among younger men, where alopecia prescriptions soon dominated over BPH uses due to the condition&#x27;s prevalence—affecting up to 50% of men over 50—and finasteride&#x27;s efficacy in stabilizing vertex and anterior mid-scalp hair loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> By the 2000s, hair loss treatment accounted for the majority of prescriptions, reflecting a pivot from urological to cosmetic applications despite the original BPH focus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Exploration for prostate cancer prevention via the Prostate Cancer Prevention Trial (PCPT, 1993–2003) revealed a 24.8% overall risk reduction but a higher incidence of high-grade (Gleason 8–10) tumors (1.8% versus 1.1% placebo), prompting no approval and label revisions in 2009–2011 to warn of potential high-grade cancer risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> Subsequent analyses suggested detection bias from finasteride&#x27;s prostate shrinkage and PSA effects may have inflated high-grade detections without elevating mortality, yet regulatory caution precluded preventive labeling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Off-label uses emerged in the 2010s, including for hirsutism in women with polycystic ovary syndrome or idiopathic causes, where randomized trials reported over 50% reductions in hirsutism scores at 5 mg doses, though without FDA endorsement due to teratogenic risks and limited large-scale data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup> Post-2020, topical formulations gained traction for alopecia to minimize systemic exposure, supported by smaller studies showing comparable efficacy to oral versions with potentially fewer side effects, but no new FDA indications materialized; compounded topicals remain unapproved, with 2025 alerts citing absorption risks and adverse event reports.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> Evidence gaps persist for long-term off-label safety, particularly in women and non-approved routes, limiting formal expansions beyond core urological and dermatological roles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="society-and-culture" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Society and Culture<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="branding-generics-and-availability" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Branding, Generics, and Availability<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride is marketed under the brand name <strong>Proscar</strong> (5 mg tablets) for the treatment of benign prostatic hyperplasia and <strong>Propecia</strong> (1 mg tablets) for male pattern hair loss, both developed by Merck &amp; Co.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Generic versions of finasteride in both 1 mg and 5 mg strengths became widely available following patent expirations; in the United States, the patent for Propecia expired in 2013, with the first generic approvals occurring on November 5, 2013, by manufacturers such as Accord Healthcare.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The entry of generics led to substantial price reductions, often exceeding 80% compared to branded versions, enhancing affordability and access for patients in regulated markets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> For instance, generic finasteride 1 mg tablets, which retailed for around $100–$150 monthly for branded Propecia pre-expiry, dropped to $10–$20 per month post-2013 in the US, depending on pharmacy and quantity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> Efforts to reclassify finasteride for over-the-counter sale, particularly for lower-dose hair loss treatment, have not succeeded in major jurisdictions due to concerns over side effects, including sexual dysfunction and teratogenic risks, maintaining its prescription-only status with mandatory patient information on handling and contraception.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Globally, finasteride is accessible in over 100 countries through approved pharmaceutical channels, with formulations authorized by bodies such as the European Medicines Agency for both oral and topical uses in men.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Availability varies by regulatory framework—prescription-required in the US, EU, UK, Canada, and Australia—but is broadly permitted except where stringent pregnancy contraindications limit distribution or require specialized handling protocols, as the drug causes genital abnormalities in male fetuses if handled by pregnant women.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> In developing regions, generics dominate supply chains, further driving down costs amid growing market demand projected to reach USD 4.6 billion by 2035.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<h3 id="use-in-athletics-and-doping" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Use in Athletics and Doping<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride, a 5α-reductase inhibitor, was added to the World Anti-Doping Agency (WADA) Prohibited List in 2005 as a masking agent capable of altering urinary steroid profiles to evade detection of exogenous anabolic-androgenic steroids, such as nandrolone and its precursors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_doabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> This inclusion stemmed from research demonstrating that finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT), thereby modifying metabolite ratios like the testosterone/epitestosterone (T/E) ratio and nandrolone indicators, which are used in doping controls.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_loabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Initial temporary therapeutic use exemptions (TUEs) for medical conditions like benign prostatic hyperplasia or androgenetic alopecia were permitted but phased out as WADA prioritized uniform enforcement, with exemptions ending by 2006 for non-essential uses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_toabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The prohibition lacked evidence of direct ergogenic (performance-enhancing) effects from finasteride alone, as its primary action reduces DHT without substantially elevating free testosterone levels or anabolic signaling in skeletal muscle.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup> DHT, derived from testosterone via 5α-reductase, plays a minor role in muscle hypertrophy compared to testosterone, and finasteride&#x27;s suppression (up to 70% in serum) has shown no significant impact on strength, endurance, or recovery in controlled studies of healthy males.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[150]</sup> Speculation on indirect effects, such as altered muscle repair via DHT&#x27;s androgen receptor affinity in prostate or skin tissues, remains unsubstantiated for athletic contexts, with empirical data indicating neutral outcomes on body composition or exercise capacity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_poqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Doping violations involving finasteride were rare and typically unintentional, linked to its prescription for hair loss rather than deliberate enhancement. Notable cases include U.S. skeleton racer Zach Lund, who tested positive in 2005 after using it for alopecia and received a temporary ban despite appealing for a retroactive TUE, and Brazilian footballer Romário, sanctioned in 2006 for similar therapeutic use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> WADA required athletes to apply for TUEs via national anti-doping organizations during the ban, with denials triggering mandatory notifications to international federations and potential suspensions; approval rates were low absent compelling medical necessity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[151]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2009, WADA removed finasteride from the Prohibited List following refinements in gas chromatography-mass spectrometry techniques that adjusted for its metabolic interference, rendering masking ineffective without compromising test specificity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[152]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup> As of 2025, it remains unprohibited in and out of competition, with no resurgence in doping concerns due to advanced biomarker profiling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[153]</sup></span>
<h3 id="public-perception-and-controversies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Public Perception and Controversies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finasteride&#x27;s use for male pattern baldness has often been stigmatized as a vanity treatment, reflecting broader societal discomfort with men addressing cosmetic hair loss through medication rather than accepting it as natural aging. This perception persists despite surveys indicating that up to 70% of men experience some degree of baldness-related self-consciousness, with cultural ideals of youth and vitality amplifying pressures on male body image.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup> Critics argue that promoting finasteride for non-life-threatening conditions like androgenetic alopecia exemplifies over-medicalization, prioritizing appearance enhancement over potential risks in otherwise healthy individuals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[155]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Online forums dedicated to post-finasteride syndrome (PFS) have significantly shaped public discourse, raising awareness of persistent side effects while sometimes fueling alarmism through anecdotal reports and unverified claims. Communities such as those hosted by the PFS Foundation have highlighted cases of severe psychological distress, with an expert witness in 2025 litigation estimating that hundreds to thousands of men may have died by suicide due to PFS-related effects since the drug&#x27;s approval.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> These platforms contrast with pharmaceutical defenses, including Merck&#x27;s historical downplaying of risks, as alleged in lawsuits and investigations revealing suppressed trial data on persistent sexual and mood issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Media coverage in 2025 intensified scrutiny following regulatory actions, with the European Medicines Agency confirming suicidal ideation as a side effect of finasteride tablets in May, prompting updated warnings and patient alert cards.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Outlets like CBC and the New York Post amplified patient testimonies of debilitating effects, shifting narratives from routine safety endorsements to calls for caution, particularly for younger users treating hair loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[156]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[157]</sup> This evolution highlights tensions between advocacy groups pushing for black-box warnings and industry responses emphasizing rarity of events, amid accusations of regulatory delays in acknowledging neuropsychiatric links.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_trqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup></span>
<h2 id="ongoing-research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Ongoing Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="recent-developments-2024-2025" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recent Developments (2024-2025)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In April 2025, the U.S. Food and Drug Administration (FDA) issued an alert regarding potential risks associated with compounded topical finasteride products, which lack FDA approval for any topical formulation. The agency reported 32 adverse drug reactions (ADRs) over the preceding five years, including erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido, and testicular pain, emphasizing risks from inconsistent compounding practices and variable absorption.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In May 2025, the European Medicines Agency&#x27;s Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets following an EU-wide review, implementing new risk mitigation measures such as updated product information to advise patients on monitoring for psychiatric symptoms. No direct causal link was established for dutasteride, though both drugs carry known psychiatric risks. These updates built on prior signals without altering overall benefit-risk profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Analyses of global pharmacovigilance databases in 2025 highlighted surges in reported finasteride-related ADRs, including a reported 10,000% week-over-week increase in WHO VigiBase entries early in the year, surpassing 2024 records by 42% and incorporating 119 new suicidality cases. Concurrent studies linked these effects to finasteride&#x27;s inhibition of 5α-reductase, which suppresses neurosteroid synthesis like allopregnanolone, potentially dysregulating mood via serotonergic pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[161]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_duabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_huabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[162]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Litigation involving Propecia (finasteride 1 mg) intensified in 2025, with lawsuits alleging underreporting of persistent neuropsychiatric effects; expert testimony in federal cases estimated hundreds to thousands of unreported suicides attributable to post-finasteride syndrome, prompting calls for systematic evidence reviews on causality. These claims, drawn from real-world adverse event data, underscore ongoing debates over long-term risk disclosure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_duqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup></span>
<h3 id="emerging-therapies-and-alternatives" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Emerging Therapies and Alternatives<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Dutasteride, a dual inhibitor of type I and II 5α-reductase enzymes, achieves greater dihydrotestosterone (DHT) suppression (98% serum reduction) compared to finasteride&#x27;s 71%, leading to superior hair regrowth in androgenetic alopecia trials, with thrice-weekly dosing showing moderate-to-marked improvement in 35% of patients versus 21% for daily finasteride.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[163]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[164]</sup> However, it carries comparable or elevated risks of sexual dysfunction and breast tenderness, with no demonstrated reduction in prostate cancer risk relative to finasteride in benign prostatic hyperplasia cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[165]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Topical formulations combining finasteride (0.25%) with minoxidil (5%) demonstrate enhanced efficacy over minoxidil monotherapy in male pattern hair loss, yielding significant improvements in hair density and diameter in 90% of users, potentially mitigating systemic absorption and side effects associated with oral administration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup> Systematic reviews confirm synergistic effects, though long-term safety data remain preliminary amid reports of adverse events with compounded topicals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Platelet-rich plasma (PRP) injections emerge as a non-pharmacological adjunct for androgenetic alopecia, stimulating follicular regeneration via growth factors with minimal side effects and efficacy comparable to or exceeding finasteride in density gains, positioning it as a viable alternative for patients averse to hormonal modulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup> Prospective comparisons indicate PRP&#x27;s adjuvant role with minoxidil yields better outcomes than finasteride-fortified topicals in some metrics, though optimal protocols require further standardization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genetic screening for variants in SRD5A1 and SRD5A2 genes shows preliminary associations with treatment response, enabling prediction of non-responders to 5α-reductase inhibitors and guiding personalized selection between finasteride and dutasteride.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup> Studies link specific polymorphisms to differential DHT metabolism and regrowth potential, though clinical utility awaits larger validation beyond niche pharmacogenetic tests.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For post-finasteride syndrome, no proven therapies exist as of 2024, with ongoing monitoring of investigational agents by advocacy groups but limited empirical support for neurosteroid or gene-based interventions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[175]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Causal mechanisms remain debated, emphasizing pre-treatment genetic evaluation to identify vulnerability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK513329/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK513329/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK513329/</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf</a></span></div></li><li id="https://www.cnbc.com/2019/09/11/court-let-merck-hide-secrets-about-baldness-drugs-risks.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cnbc.com/2019/09/11/court-let-merck-hide-secrets-about-baldness-drugs-risks.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cnbc.com/2019/09/11/court-let-merck-hide-secrets-about-baldness-drugs-risks.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0090429598006669" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0090429598006669" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0090429598006669</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9951956/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9951956/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9951956/</a></span></div></li><li id="https://gmr.scholasticahq.com/article/88531-finasteride-and-dutasteride-for-the-treatment-of-male-androgenetic-alopecia-a-review-of-efficacy-and-reproductive-adverse-effect" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://gmr.scholasticahq.com/article/88531-finasteride-and-dutasteride-for-the-treatment-of-male-androgenetic-alopecia-a-review-of-efficacy-and-reproductive-adverse-effect" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://gmr.scholasticahq.com/article/88531-finasteride-and-dutasteride-for-the-treatment-of-male-androgenetic-alopecia-a-review-of-efficacy-and-reproductive-adverse-effect</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S235228951930061X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S235228951930061X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S235228951930061X</a></span></div></li><li id="https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0015028219325993" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0015028219325993" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0015028219325993</a></span></div></li><li id="https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK555930/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK555930/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK555930/</a></span></div></li><li id="https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.1993.tb02739.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.1993.tb02739.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.1993.tb02739.x</a></span></div></li><li id="https://tau.amegroups.org/article/view/111026/html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://tau.amegroups.org/article/view/111026/html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://tau.amegroups.org/article/view/111026/html</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4064044/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4064044/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4064044/</a></span></div></li><li id="https://karger.com/nen/article/103/6/746/220377/Effects-of-Subchronic-Finasteride-Treatment-and" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/nen/article/103/6/746/220377/Effects-of-Subchronic-Finasteride-Treatment-and" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/nen/article/103/6/746/220377/Effects-of-Subchronic-Finasteride-Treatment-and</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1347436715300239" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1347436715300239" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1347436715300239</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8846625/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8846625/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8846625/</a></span></div></li><li id="https://go.drugbank.com/drugs/DB01216" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB01216" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB01216</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s033lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s033lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s033lbl.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJM199210223271701" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJM199210223271701" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJM199210223271701</a></span></div></li><li id="https://reference.medscape.com/drug/propecia-proscar-finasteride-342824" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://reference.medscape.com/drug/propecia-proscar-finasteride-342824" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://reference.medscape.com/drug/propecia-proscar-finasteride-342824</a></span></div></li><li id="https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJM199802263380901" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJM199802263380901" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJM199802263380901</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa030656" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa030656" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa030656</a></span></div></li><li id="https://www.va.gov/formularyadvisor/DOC_PDF/Alpha_Blocker_and_Finasteride_Combination_Therapy_for_BPH.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.va.gov/formularyadvisor/DOC_PDF/Alpha_Blocker_and_Finasteride_Combination_Therapy_for_BPH.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.va.gov/formularyadvisor/DOC_PDF/Alpha_Blocker_and_Finasteride_Combination_Therapy_for_BPH.pdf</a></span></div></li><li id="https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline</a></span></div></li><li id="https://www.drugs.com/finasteride.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/finasteride.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/finasteride.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9777765/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9777765/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9777765/</a></span></div></li><li id="https://www.uspharmacist.com/article/treatment-options-for-androgenic-alopecia-10959" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uspharmacist.com/article/treatment-options-for-androgenic-alopecia-10959" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uspharmacist.com/article/treatment-options-for-androgenic-alopecia-10959</a></span></div></li><li id="https://ijdvl.com/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ijdvl.com/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ijdvl.com/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0365059623000533" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0365059623000533" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0365059623000533</a></span></div></li><li id="https://miiskin.com/hair-loss/medications-for-hair-loss/finasteride-for-women/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://miiskin.com/hair-loss/medications-for-hair-loss/finasteride-for-women/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://miiskin.com/hair-loss/medications-for-hair-loss/finasteride-for-women/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/</a></span></div></li><li id="https://www.mdpi.com/2077-0383/13/11/3052" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/13/11/3052" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/13/11/3052</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10526249/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10526249/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10526249/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0015028204009240" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0015028204009240" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0015028204009240</a></span></div></li><li id="https://academic.oup.com/jcem/article/85/1/89/2852067" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jcem/article/85/1/89/2852067" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jcem/article/85/1/89/2852067</a></span></div></li><li id="https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf&amp;lang=en" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf&amp;lang=en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf&amp;lang=en</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/30604525/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/30604525/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/30604525/</a></span></div></li><li id="https://jamanetwork.com/journals/jamadermatology/fullarticle/403800" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/403800" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamadermatology/fullarticle/403800</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/41024043/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/41024043/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/41024043/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12482827/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12482827/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12482827/</a></span></div></li><li id="https://www.drugs.com/pregnancy/finasteride.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/pregnancy/finasteride.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/pregnancy/finasteride.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/29855987/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/29855987/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/29855987/</a></span></div></li><li id="https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa030660" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa030660" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa030660</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8804493/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8804493/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8804493/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/</a></span></div></li><li id="https://www.auajournals.org/doi/10.1016/j.juro.2010.11.060" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.auajournals.org/doi/10.1016/j.juro.2010.11.060" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.auajournals.org/doi/10.1016/j.juro.2010.11.060</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/11809594/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/11809594/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/11809594/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/28396101/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/28396101/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/28396101/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10510925/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10510925/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10510925/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2008.01785.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2008.01785.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2008.01785.x</a></span></div></li><li id="https://www.oatext.com/Long-term-%2810-year%29-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.oatext.com/Long-term-%2810-year%29-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.oatext.com/Long-term-%2810-year%29-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php</a></span></div></li><li id="https://emedicine.medscape.com/article/1070167-treatment" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/1070167-treatment" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/1070167-treatment</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0022202X15529357" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0022202X15529357" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0022202X15529357</a></span></div></li><li id="https://academic.oup.com/jnci/article/99/18/1375/923438" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jnci/article/99/18/1375/923438" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jnci/article/99/18/1375/923438</a></span></div></li><li id="https://aacrjournals.org/cancerpreventionresearch/article/1/3/174/46398/Finasteride-Does-Not-Increase-the-Risk-of-High" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://aacrjournals.org/cancerpreventionresearch/article/1/3/174/46398/Finasteride-Does-Not-Increase-the-Risk-of-High" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://aacrjournals.org/cancerpreventionresearch/article/1/3/174/46398/Finasteride-Does-Not-Increase-the-Risk-of-High</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/30206635/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/30206635/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/30206635/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40473994/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40473994/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40473994/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/</a></span></div></li><li id="https://www.mdpi.com/1424-8247/18/7/957" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/1424-8247/18/7/957" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/1424-8247/18/7/957</a></span></div></li><li id="https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines</a></span></div></li><li id="https://www.medscape.com/viewarticle/ema-decision-finasteride-linked-suicidal-ideation-2025a1000b9x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medscape.com/viewarticle/ema-decision-finasteride-linked-suicidal-ideation-2025a1000b9x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medscape.com/viewarticle/ema-decision-finasteride-linked-suicidal-ideation-2025a1000b9x</a></span></div></li><li id="https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/</a></span></div></li><li id="https://www.healio.com/news/dermatology/20201203/suicidality-depression-anxiety-higher-in-younger-patients-on-finasteride-for-alopecia" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healio.com/news/dermatology/20201203/suicidality-depression-anxiety-higher-in-younger-patients-on-finasteride-for-alopecia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healio.com/news/dermatology/20201203/suicidality-depression-anxiety-higher-in-younger-patients-on-finasteride-for-alopecia</a></span></div></li><li id="https://www.pfsfoundation.org/news/young-men-using-finasteride-for-alopecia-may-be-more-suicide-prone-than-the-general-population-says-new-pharmacovigilance-research/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/news/young-men-using-finasteride-for-alopecia-may-be-more-suicide-prone-than-the-general-population-says-new-pharmacovigilance-research/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/news/young-men-using-finasteride-for-alopecia-may-be-more-suicide-prone-than-the-general-population-says-new-pharmacovigilance-research/</a></span></div></li><li id="https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1526820918308371" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1526820918308371" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1526820918308371</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11040274/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11040274/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11040274/</a></span></div></li><li id="https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancer" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancer</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5773955/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5773955/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5773955/</a></span></div></li><li id="https://aacrjournals.org/cebp/article/28/5/980/71689/Finasteride-Use-and-Risk-of-Male-Breast-Cancer-A" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://aacrjournals.org/cebp/article/28/5/980/71689/Finasteride-Use-and-Risk-of-Male-Breast-Cancer-A" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://aacrjournals.org/cebp/article/28/5/980/71689/Finasteride-Use-and-Risk-of-Male-Breast-Cancer-A</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/16093979/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/16093979/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/16093979/</a></span></div></li><li id="https://academic.oup.com/jnci/article/98/16/1128/2521721" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jnci/article/98/16/1128/2521721" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jnci/article/98/16/1128/2521721</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7308241/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7308241/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7308241/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/21418145/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/21418145/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/21418145/</a></span></div></li><li id="https://www.pfsfoundation.org/pfs-by-the-numbers/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/pfs-by-the-numbers/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/pfs-by-the-numbers/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22789024/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22789024/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22789024/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5155688/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5155688/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5155688/</a></span></div></li><li id="https://www.mdpi.com/2218-273X/15/7/1044" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2218-273X/15/7/1044" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2218-273X/15/7/1044</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36358917/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36358917/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36358917/</a></span></div></li><li id="https://journals.physiology.org/doi/abs/10.1152/physiol.2024.39.S1.1269" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.physiology.org/doi/abs/10.1152/physiol.2024.39.S1.1269" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.physiology.org/doi/abs/10.1152/physiol.2024.39.S1.1269</a></span></div></li><li id="https://www.researchgate.net/publication/353127752_Differential_Gene_Expression_in_Post-Finasteride_Syndrome_Patients" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/353127752_Differential_Gene_Expression_in_Post-Finasteride_Syndrome_Patients" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/353127752_Differential_Gene_Expression_in_Post-Finasteride_Syndrome_Patients</a></span></div></li><li id="https://www.pfsfoundation.org/news/finasteride-induced-suicides-up-8-4-in-whos-vigibase/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/news/finasteride-induced-suicides-up-8-4-in-whos-vigibase/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/news/finasteride-induced-suicides-up-8-4-in-whos-vigibase/</a></span></div></li><li id="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309849" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309849" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309849</a></span></div></li><li id="https://www.pfsnetwork.org/science/y77lkfbdtqfnn42n5n9cvjzdqmsjd1-IZCIP" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsnetwork.org/science/y77lkfbdtqfnn42n5n9cvjzdqmsjd1-IZCIP" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsnetwork.org/science/y77lkfbdtqfnn42n5n9cvjzdqmsjd1-IZCIP</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243</a></span></div></li><li id="https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf</a></span></div></li><li id="https://www.dermatologyadvisor.com/news/concerns-over-compounded-topical-finasteride-prompt-fda-alert/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dermatologyadvisor.com/news/concerns-over-compounded-topical-finasteride-prompt-fda-alert/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dermatologyadvisor.com/news/concerns-over-compounded-topical-finasteride-prompt-fda-alert/</a></span></div></li><li id="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025</a></span></div></li><li id="https://www.drugwatch.com/propecia/lawsuits/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/propecia/lawsuits/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/propecia/lawsuits/</a></span></div></li><li id="https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/</a></span></div></li><li id="https://www.citizen.org/news/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.citizen.org/news/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.citizen.org/news/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10495375/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10495375/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10495375/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9295476/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9295476/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9295476/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36386264/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36386264/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36386264/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/</a></span></div></li><li id="https://www.ishrs-htforum.org/content/28/3/112" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ishrs-htforum.org/content/28/3/112" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ishrs-htforum.org/content/28/3/112</a></span></div></li><li id="https://perfecthairhealth.com/does-topical-finasteride-work/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://perfecthairhealth.com/does-topical-finasteride-work/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://perfecthairhealth.com/does-topical-finasteride-work/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34634163/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34634163/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34634163/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/ijd.17957" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/ijd.17957" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/ijd.17957</a></span></div></li><li id="https://nabp.pharmacy/news/blog/regulatory_news/compounded-topical-finasteride-products-associated-with-serious-risks/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nabp.pharmacy/news/blog/regulatory_news/compounded-topical-finasteride-products-associated-with-serious-risks/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nabp.pharmacy/news/blog/regulatory_news/compounded-topical-finasteride-products-associated-with-serious-risks/</a></span></div></li><li id="https://www.ijbamr.com/assets/images/issues/pdf/71nag2_6w0c1i_34kUVI_YI8x3j_177107.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ijbamr.com/assets/images/issues/pdf/71nag2_6w0c1i_34kUVI_YI8x3j_177107.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ijbamr.com/assets/images/issues/pdf/71nag2_6w0c1i_34kUVI_YI8x3j_177107.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40662444/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40662444/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40662444/</a></span></div></li><li id="https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/</a></span></div></li><li id="https://hcplive.com/view/study-compares-safety-findings-oral-versus-topical-finasteride-for-alopecia" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hcplive.com/view/study-compares-safety-findings-oral-versus-topical-finasteride-for-alopecia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://hcplive.com/view/study-compares-safety-findings-oral-versus-topical-finasteride-for-alopecia</a></span></div></li><li id="https://www.endocrine-abstracts.org/ea/0021/ea0021p43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.endocrine-abstracts.org/ea/0021/ea0021p43" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.endocrine-abstracts.org/ea/0021/ea0021p43</a></span></div></li><li id="https://www.urologytimes.com/view/psa-adjustments-are-required-men-taking-5-aris" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.urologytimes.com/view/psa-adjustments-are-required-men-taking-5-aris" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.urologytimes.com/view/psa-adjustments-are-required-men-taking-5-aris</a></span></div></li><li id="https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/15992088/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/15992088/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/15992088/</a></span></div></li><li id="https://insights.citeline.com/PS021070/MERCKs-PROSCAR-FINASTERIDE-APPROVED-JUNE-19-AFTER-14MONTH-REVIEW/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://insights.citeline.com/PS021070/MERCKs-PROSCAR-FINASTERIDE-APPROVED-JUNE-19-AFTER-14MONTH-REVIEW/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://insights.citeline.com/PS021070/MERCKs-PROSCAR-FINASTERIDE-APPROVED-JUNE-19-AFTER-14MONTH-REVIEW/</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf</a></span></div></li><li id="https://conexiant.com/dermatology/articles/fda-warns-of-topical-finasteride-risks/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://conexiant.com/dermatology/articles/fda-warns-of-topical-finasteride-risks/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://conexiant.com/dermatology/articles/fda-warns-of-topical-finasteride-risks/</a></span></div></li><li id="https://upguys.com/blog/finasteride-mechanism-of-action" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://upguys.com/blog/finasteride-mechanism-of-action" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://upguys.com/blog/finasteride-mechanism-of-action</a></span></div></li><li id="https://finasterideinfo.org/regulation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://finasterideinfo.org/regulation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://finasterideinfo.org/regulation/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/7505970/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/7505970/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/7505970/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa1215932" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1215932" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa1215932</a></span></div></li><li id="https://www.jaad.org/article/S0190-9622%2898%2970007-6/abstract" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jaad.org/article/S0190-9622%2898%2970007-6/abstract" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jaad.org/article/S0190-9622%2898%2970007-6/abstract</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf</a></span></div></li><li id="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961690-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961690-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961690-X/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/17848673/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/17848673/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/17848673/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0015028216583885" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0015028216583885" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0015028216583885</a></span></div></li><li id="https://www.webmd.com/drugs/2/drug-1548-167/finasteride-oral/finasteride-oral/details" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.webmd.com/drugs/2/drug-1548-167/finasteride-oral/finasteride-oral/details" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.webmd.com/drugs/2/drug-1548-167/finasteride-oral/finasteride-oral/details</a></span></div></li><li id="https://www.drugs.com/availability/generic-propecia.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/availability/generic-propecia.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/availability/generic-propecia.html</a></span></div></li><li id="https://www.drugpatentwatch.com/p/generic-api/FINASTERIDE" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugpatentwatch.com/p/generic-api/FINASTERIDE" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugpatentwatch.com/p/generic-api/FINASTERIDE</a></span></div></li><li id="https://www.drugpatentwatch.com/p/drug-price/drugname/FINASTERIDE" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugpatentwatch.com/p/drug-price/drugname/FINASTERIDE" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugpatentwatch.com/p/drug-price/drugname/FINASTERIDE</a></span></div></li><li id="https://www.doctorfox.co.uk/news/patent-for-propecia-expires-in-the-uk/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.doctorfox.co.uk/news/patent-for-propecia-expires-in-the-uk/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.doctorfox.co.uk/news/patent-for-propecia-expires-in-the-uk/</a></span></div></li><li id="https://www.goodrx.com/finasteride" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.goodrx.com/finasteride" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.goodrx.com/finasteride</a></span></div></li><li id="https://www.hims.com/blog/is-finasteride-over-the-counter" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hims.com/blog/is-finasteride-over-the-counter" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hims.com/blog/is-finasteride-over-the-counter</a></span></div></li><li id="https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products</a></span></div></li><li id="https://www.researchnester.com/reports/finasteride-market/2984" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchnester.com/reports/finasteride-market/2984" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchnester.com/reports/finasteride-market/2984</a></span></div></li><li id="https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2005_EN.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2005_EN.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2005_EN.pdf</a></span></div></li><li id="https://www.wada-ama.org/en/resources/scientific-research/investigation-about-deffects-and-detection-finasteride-substance" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wada-ama.org/en/resources/scientific-research/investigation-about-deffects-and-detection-finasteride-substance" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wada-ama.org/en/resources/scientific-research/investigation-about-deffects-and-detection-finasteride-substance</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/17417080/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/17417080/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/17417080/</a></span></div></li><li id="https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34318592/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34318592/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34318592/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4073894/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4073894/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4073894/</a></span></div></li><li id="https://www.wada-ama.org/en/athletes-support-personnel/therapeutic-use-exemptions-tues" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wada-ama.org/en/athletes-support-personnel/therapeutic-use-exemptions-tues" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wada-ama.org/en/athletes-support-personnel/therapeutic-use-exemptions-tues</a></span></div></li><li id="https://www.abc.net.au/news/2008-10-28/hair-loss-drug-wiped-from-doping-banned-list/184554" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.abc.net.au/news/2008-10-28/hair-loss-drug-wiped-from-doping-banned-list/184554" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.abc.net.au/news/2008-10-28/hair-loss-drug-wiped-from-doping-banned-list/184554</a></span></div></li><li id="https://www.wada-ama.org/en/prohibited-list" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wada-ama.org/en/prohibited-list" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wada-ama.org/en/prohibited-list</a></span></div></li><li id="https://www.bbc.com/news/health-44052917" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/health-44052917" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.com/news/health-44052917</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/dth.12647" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/dth.12647" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/dth.12647</a></span></div></li><li id="https://www.cbc.ca/news/health/hair-loss-drug-finasteride-side-effects-1.7483898" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cbc.ca/news/health/hair-loss-drug-finasteride-side-effects-1.7483898" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cbc.ca/news/health/hair-loss-drug-finasteride-side-effects-1.7483898</a></span></div></li><li id="https://nypost.com/2025/10/08/health/hair-loss-treatment-used-by-millions-linked-to-suicide-risk/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nypost.com/2025/10/08/health/hair-loss-treatment-used-by-millions-linked-to-suicide-risk/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nypost.com/2025/10/08/health/hair-loss-treatment-used-by-millions-linked-to-suicide-risk/</a></span></div></li><li id="https://www.medicalbrief.co.za/fda-merck-accused-of-covering-up-hair-loss-pills-suicide-link/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medicalbrief.co.za/fda-merck-accused-of-covering-up-hair-loss-pills-suicide-link/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medicalbrief.co.za/fda-merck-accused-of-covering-up-hair-loss-pills-suicide-link/</a></span></div></li><li id="https://www.consumermedsafety.org/safety-articles/risks-of-topical-finasteride" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.consumermedsafety.org/safety-articles/risks-of-topical-finasteride" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.consumermedsafety.org/safety-articles/risks-of-topical-finasteride</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf</a></span></div></li><li id="https://www.pfsfoundation.org/news/finasteride-adrs-soar-10000-week-over-week-says-world-health-organization/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/news/finasteride-adrs-soar-10000-week-over-week-says-world-health-organization/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/news/finasteride-adrs-soar-10000-week-over-week-says-world-health-organization/</a></span></div></li><li id="https://www.sciencedaily.com/releases/2025/10/251013040343.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedaily.com/releases/2025/10/251013040343.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedaily.com/releases/2025/10/251013040343.htm</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9561294/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9561294/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9561294/</a></span></div></li><li id="https://www.jaadinternational.org/article/S2666-3287%2825%2900101-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jaadinternational.org/article/S2666-3287%2825%2900101-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jaadinternational.org/article/S2666-3287%2825%2900101-4/fulltext</a></span></div></li><li id="https://www.innerbody.com/dutasteride-vs-finasteride" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.innerbody.com/dutasteride-vs-finasteride" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.innerbody.com/dutasteride-vs-finasteride</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12537375/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12537375/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12537375/</a></span></div></li><li id="https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/</a></span></div></li><li id="https://www.healio.com/news/dermatology/20241205/topical-finasteride-minoxidil-combination-efficacious-in-male-androgenic-alopecia" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healio.com/news/dermatology/20241205/topical-finasteride-minoxidil-combination-efficacious-in-male-androgenic-alopecia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healio.com/news/dermatology/20241205/topical-finasteride-minoxidil-combination-efficacious-in-male-androgenic-alopecia</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7216252/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7216252/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7216252/</a></span></div></li><li id="https://scandinavianbiolabs.com/blogs/hair-loss/prp-vs-finasteride" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://scandinavianbiolabs.com/blogs/hair-loss/prp-vs-finasteride" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://scandinavianbiolabs.com/blogs/hair-loss/prp-vs-finasteride</a></span></div></li><li id="https://ijced.org/archive/volume/8/issue/2/article/7808" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ijced.org/archive/volume/8/issue/2/article/7808" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ijced.org/archive/volume/8/issue/2/article/7808</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6746394/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6746394/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6746394/</a></span></div></li><li id="https://perfecthairhealth.com/srd5a1-2-can-these-genes-predict-regrowth-from-5-alpha-reductase-inhibitors/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://perfecthairhealth.com/srd5a1-2-can-these-genes-predict-regrowth-from-5-alpha-reductase-inhibitors/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://perfecthairhealth.com/srd5a1-2-can-these-genes-predict-regrowth-from-5-alpha-reductase-inhibitors/</a></span></div></li><li id="https://www.albareyes.com/genetic-tests/genetic-tests-for-finasteride-response/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.albareyes.com/genetic-tests/genetic-tests-for-finasteride-response/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.albareyes.com/genetic-tests/genetic-tests-for-finasteride-response/</a></span></div></li><li id="https://www.pfsfoundation.org/research/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pfsfoundation.org/research/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pfsfoundation.org/research/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9641066/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9641066/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9641066/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1" id="_R_" async=""></script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Finasteride\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Finasteride\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Finasteride\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T1312f,"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"# Finasteride\n\n![Finasteride chemical structure](./_assets_/Finasteride.svg.png)  \nFinasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT).[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf) By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) Developed by Merck \u0026 Co., it received U.S. Food and Drug Administration (FDA) approval in 1992 at a 5 mg dose (Proscar) for BPH and in 1997 at a 1 mg dose (Propecia) for male pattern hair loss.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf)[](https://www.cnbc.com/2019/09/11/court-let-merck-hide-secrets-about-baldness-drugs-risks.html)  \n\nClinical trials demonstrate finasteride's efficacy in reducing BPH progression and complications in men with enlarged prostates, with sustained improvements in urinary symptoms and flow rates over years of use.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/)[](https://www.sciencedirect.com/science/article/abs/pii/S0090429598006669) For androgenetic alopecia, it increases hair count and prevents further loss in a majority of users, outperforming placebo in randomized studies, though benefits reverse upon discontinuation.[](https://pubmed.ncbi.nlm.nih.gov/9951956/)[](https://gmr.scholasticahq.com/article/88531-finasteride-and-dutasteride-for-the-treatment-of-male-androgenetic-alopecia-a-review-of-efficacy-and-reproductive-adverse-effect)  \n\nDespite its therapeutic successes, finasteride is associated with adverse effects, including reduced libido, erectile dysfunction, and ejaculatory disorders, which occur in 1-5% of users and may persist beyond treatment cessation in a subset of cases, a condition termed post-finasteride syndrome (PFS).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/)[](https://www.sciencedirect.com/science/article/pii/S235228951930061X) Empirical evidence from patient reports, clinical observations, and small-scale studies supports the existence of persistent sexual, neurological, and psychological symptoms in some individuals, though large-scale causality remains debated due to challenges in study design and low incidence rates.[](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972)[](https://www.sciencedirect.com/science/article/pii/S0015028219325993) Long-term use also elevates risks of high-grade prostate cancer detection in some analyses, prompting updated FDA warnings.[](https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327) These risks underscore the need for informed consent, particularly given DHT's role in male physiology.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/)\n\n## Pharmacology\n\n### Pharmacodynamics\n\nFinasteride functions as a selective, competitive inhibitor of the type II isoenzyme of steroid 5α-reductase, an NADPH-dependent enzyme that catalyzes the irreversible reduction of testosterone to dihydrotestosterone (DHT) at the Δ4-3-keto position of the steroid A ring.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) This inhibition disrupts the primary biochemical pathway for DHT biosynthesis, which exhibits approximately threefold higher potency than testosterone in binding to the androgen receptor due to its reduced affinity for sex hormone-binding globulin and enhanced transcriptional activation in target tissues.[](https://www.ncbi.nlm.nih.gov/books/NBK555930/) The binding of finasteride to the enzyme's active site forms a stable enzyme-inhibitor complex, preventing substrate access and thereby reducing DHT production without directly affecting testosterone synthesis or other upstream steroidogenic enzymes.[](https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.1993.tb02739.x)\n\nIn systemic circulation, daily oral dosing of 5 mg finasteride achieves approximately 65-70% suppression of serum DHT levels within 24 hours, stabilizing at this reduction with continued administration, while prostate tissue DHT concentrations decline by 80-90% due to the predominance of type II 5α-reductase expression in prostatic epithelium and stroma.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) Scalp dermal papilla cells, also enriched in type II isoenzyme, experience comparable localized DHT depletion of 60-70%, contrasting with minimal alterations in serum testosterone, which may rise modestly (8-15%) as a compensatory feedback from reduced metabolic clearance to DHT.[](https://tau.amegroups.org/article/view/111026/html) This tissue-specificity arises from differential isoenzyme distribution—type II prevailing in genital skin, prostate, and hair follicles—allowing finasteride to attenuate DHT-dependent androgen signaling in these sites without broadly impairing testosterone-mediated pathways elsewhere.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf)\n\nInitial enzyme blockade preserves levels of unconverted androgens and type I 5α-reductase substrates, but sustained inhibition can indirectly perturb downstream cascades, including potential reductions in neuroactive steroids derived from progesterone and deoxycorticosterone via 5α-reduction in the central nervous system, where type II activity contributes modestly alongside type I.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4064044/) Such alterations may modulate GABA_A receptor allosteric function through decreased allopregnanolone, influencing neuronal excitability, though the net impact on androgen receptor hypersensitivity or epigenetic adaptations in DHT-sensitive tissues remains under investigation and tied to duration of exposure.[](https://karger.com/nen/article/103/6/746/220377/Effects-of-Subchronic-Finasteride-Treatment-and) Long-term pharmacodynamic modeling indicates near-complete saturation of type II inhibition at standard doses, with dose-independent plateauing of DHT suppression beyond 1-5 mg daily.[](https://www.sciencedirect.com/science/article/pii/S1347436715300239)\n\n### Pharmacokinetics\n\nFinasteride is rapidly absorbed following oral administration, with an absolute bioavailability of approximately 65% that is unaffected by concomitant food intake. Peak plasma concentrations occur within 1 to 2 hours after dosing. Steady-state plasma levels are achieved after approximately 3 days of daily dosing.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf)\n\nThe apparent volume of distribution at steady state averages 76 liters (range 44-96 liters). Circulating finasteride is approximately 90% bound to plasma proteins. Finasteride distributes into semen, where concentrations average 1.5-fold higher than simultaneous serum levels, though the total amount per ejaculate represents less than 0.001% of the daily dose.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf)[](https://pubmed.ncbi.nlm.nih.gov/8846625/)\n\nFinasteride undergoes extensive first-pass hepatic metabolism, primarily via cytochrome P450 3A4, to pharmacologically inactive metabolites including monocarboxylic acid and glucuronide conjugates.[](https://go.drugbank.com/drugs/DB01216)\n\nThe terminal elimination half-life averages 5-6 hours (range 3-16 hours) in younger men (aged 18-60 years) and approximately 8 hours (range 6-15 hours) in elderly men over 70 years, reflecting modestly reduced clearance with age. Nonlinear pharmacokinetics occur due to saturable binding to 5α-reductase; thus, steady-state plasma concentrations after 1 mg daily (mean ~9 ng/mL) are disproportionately lower relative to those after 5 mg daily (mean ~37 ng/mL). Excretion is predominantly fecal (57%, range 51-64%) with the remainder urinary (39%, range 32-46%), almost entirely as metabolites. Less than 0.1% of the dose is recovered unchanged in urine.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s033lbl.pdf)[](https://pubmed.ncbi.nlm.nih.gov/8846625/)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf)\n\n## Clinical Indications\n\n### Benign Prostatic Hyperplasia\n\nFinasteride is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate, where it reduces prostate volume and thereby alleviates associated lower urinary tract symptoms.[](https://www.nejm.org/doi/full/10.1056/NEJM199210223271701) By selectively inhibiting the type II isoform of 5α-reductase, the enzyme that converts testosterone to the more potent androgen dihydrotestosterone (DHT), finasteride lowers serum DHT levels by approximately 70% and intraprostatic DHT by 80-90%, promoting apoptosis of prostate epithelial cells and inhibiting further glandular hyperplasia driven by androgen signaling.[](https://go.drugbank.com/drugs/DB01216)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/) This DHT suppression targets the underlying pathophysiology of BPH, where elevated local DHT concentrations contribute to prostate enlargement beyond 30-40 grams in volume.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/)\n\nThe standard therapeutic dose for BPH is 5 mg administered orally once daily, with full effects on prostate size and symptom improvement generally requiring 6-12 months of continuous treatment.[](https://reference.medscape.com/drug/propecia-proscar-finasteride-342824)[](https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819) Prostate volume typically decreases by 18-20% after 12 months of 5 mg daily therapy, facilitating reduced urethral compression and enhanced bladder emptying.[](https://www.nejm.org/doi/full/10.1056/NEJM199210223271701)\n\nThis volume reduction correlates with improvements in urinary flow dynamics, including increased maximum urinary flow rates and decreased post-void residual urine volumes, which help mitigate obstructive symptoms such as hesitancy, weak stream, and incomplete voiding.[](https://www.nejm.org/doi/full/10.1056/NEJM199210223271701) Additionally, by shrinking the prostate, finasteride lowers the likelihood of acute urinary retention, a common BPH complication necessitating catheterization or surgery.[](https://www.nejm.org/doi/full/10.1056/NEJM199802263380901)\n\nIn cases of moderate-to-severe symptomatic BPH, particularly with prostates larger than 40 grams, combination therapy pairing finasteride with an alpha-1 adrenergic blocker (e.g., doxazosin at up to 8 mg daily) is often employed to achieve synergistic effects: the 5α-reductase inhibitor addresses static obstruction from prostate enlargement, while the alpha-blocker rapidly relaxes prostatic smooth muscle to relieve dynamic components of outflow resistance.[](https://www.nejm.org/doi/full/10.1056/NEJMoa030656)[](https://www.va.gov/formularyadvisor/DOC_PDF/Alpha_Blocker_and_Finasteride_Combination_Therapy_for_BPH.pdf) This approach is supported by clinical guidelines for patients at higher risk of disease progression.[](https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline)\n\n### Androgenetic Alopecia\n\nFinasteride is approved by the U.S. Food and Drug Administration for the treatment of androgenetic alopecia in men, utilizing a 1 mg daily oral dose to address progressive hair follicle miniaturization driven by dihydrotestosterone (DHT).[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf) This regimen, marketed as Propecia since its approval on December 19, 1997, focuses on men experiencing vertex and anterior mid-scalp pattern hair loss, excluding those with frontal baldness or receding hairline at the temples.[](https://www.drugs.com/finasteride.html) The therapy requires ongoing use, as benefits diminish upon cessation, with hair counts reverting to baseline within approximately one year.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/)\n\nThe mechanism involves competitive inhibition of type II 5α-reductase, the enzyme primarily expressed in scalp hair follicles that converts testosterone to DHT, thereby reducing scalp DHT concentrations by 60-70%.[](https://pubmed.ncbi.nlm.nih.gov/9777765/)[](https://www.uspharmacist.com/article/treatment-options-for-androgenic-alopecia-10959) This targeted DHT suppression interrupts the androgen-dependent shortening of the anagen phase and follicle shrinkage characteristic of androgenetic alopecia, without fully eliminating DHT production or halting loss entirely.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) Doses as low as 0.2 mg daily have shown DHT-lowering effects, but 1 mg optimizes scalp-specific inhibition while minimizing systemic impact compared to the 5 mg dose for benign prostatic hyperplasia.[](https://ijdvl.com/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia/)\n\nUse in women remains unapproved due to limited efficacy data and teratogenic risks, as finasteride can induce genital abnormalities in male fetuses via DHT suppression during critical developmental windows.[](https://www.sciencedirect.com/science/article/pii/S0365059623000533)[](https://miiskin.com/hair-loss/medications-for-hair-loss/finasteride-for-women/) It is contraindicated in pregnant or potentially pregnant women, with off-label application restricted to postmenopausal cases under specialist oversight, where small studies report variable hair density improvements but insufficient large-scale validation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/) Systemic exposure must be avoided, prompting exploration of topical formulations to mitigate fetal risks, though oral use demands strict contraception in premenopausal patients.[](https://www.mdpi.com/2077-0383/13/11/3052)\n\n### Hirsutism and Other Uses\n\nFinasteride is employed off-label for treating hirsutism in premenopausal women, particularly those with polycystic ovary syndrome (PCOS), at dosages typically ranging from 2.5 to 5 mg daily or intermittently to suppress dihydrotestosterone (DHT) levels and reduce androgen-dependent hair growth.[](https://pubmed.ncbi.nlm.nih.gov/10526249/)[](https://www.sciencedirect.com/science/article/pii/S0015028204009240) Randomized trials have demonstrated reductions in Ferriman-Gallwey hirsutism scores by 31-34% and hair shaft diameter by 27-34% after 6-12 months of treatment, with efficacy comparable to anti-androgens like spironolactone or flutamide when used as monotherapy or adjunctively.[](https://pubmed.ncbi.nlm.nih.gov/10526249/)[](https://academic.oup.com/jcem/article/85/1/89/2852067) Systematic reviews confirm improvements over placebo, especially beyond six months, though benefits are modest and require ongoing use to maintain.[](https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf\u0026lang=en)\n\nEvidence for finasteride's role in hirsutism remains limited by small sample sizes in available randomized controlled trials (often n\u003c100) and a lack of large-scale, long-term studies assessing sustained efficacy or comparative superiority over established therapies.[](https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf\u0026lang=en) Side effects reported include dry skin, decreased libido, and headache, with higher incidence at 5 mg doses, though overall tolerability is favorable in short-term data; postmenopausal use shows similar patterns but with even sparser evidence.[](https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf\u0026lang=en)[](https://pubmed.ncbi.nlm.nih.gov/30604525/)\n\nInvestigational applications extend to conditions involving androgen excess, such as acne and seborrhea within seborrhea-acne-hirsutism-alopecia (SAHA) syndrome, where low-dose finasteride (e.g., 2.5 mg/day) has shown preliminary hair regrowth and symptom reduction in case series, but randomized data are absent.[](https://jamanetwork.com/journals/jamadermatology/fullarticle/403800) In transgender care, finasteride is explored off-label for mitigating androgenetic alopecia in transgender men on testosterone therapy, with case series reporting efficacy rates akin to cisgender males (up to 87% stabilization or regrowth at 1 mg/day), though without interference to masculinization; use in transfeminine individuals for hair preservation alongside estrogen lacks robust trials.[](https://pubmed.ncbi.nlm.nih.gov/41024043/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12482827/) These roles highlight empirical gaps, relying on non-randomized or small-cohort evidence rather than definitive clinical validation.\n\nFinasteride is contraindicated in women who are pregnant or may become pregnant due to its potential to cause abnormal external genitalia development, such as hypospadias, in male fetuses via 5α-reductase inhibition during critical embryogenesis.[](https://www.drugs.com/pregnancy/finasteride.html)[](https://pubmed.ncbi.nlm.nih.gov/29855987/) Animal studies and mechanistic data underpin this risk, classifying it as pregnancy category X, with even topical exposure or handling of crushed tablets advised against; no human epidemiological excess has been confirmed for paternal preconception use, but maternal administration poses direct teratogenic threat.[](https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819)[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded)\n\n## Efficacy Evidence\n\n### Studies on BPH\n\nThe Medical Therapy of Prostatic Symptoms (MTOPS) trial, a multicenter randomized controlled trial enrolling 3047 men with moderate to severe benign prostatic hyperplasia (BPH) symptoms, found that finasteride at 5 mg daily reduced the overall risk of clinical progression by 34% compared to placebo over a median follow-up of 4.8 years (hazard ratio 0.66; 95% CI 0.53-0.81).[](https://www.nejm.org/doi/full/10.1056/NEJMoa030660) Clinical progression was a composite endpoint including a ≥4-point worsening in American Urological Association Symptom Score (AUAss), acute urinary retention, urinary tract infection, incontinence, or need for invasive therapy. Finasteride monotherapy also improved peak urinary flow rate by 1.6 mL/s and reduced prostate volume by approximately 18% relative to placebo, with benefits accumulating over time.[](https://www.nejm.org/doi/full/10.1056/NEJMoa030660)\n\nMeta-analyses of randomized controlled trials (RCTs) have corroborated these findings, showing finasteride yields modest but statistically significant improvements in International Prostate Symptom Score (IPSS) of 2-4 points greater than placebo after 6-12 months, with effects sustained in long-term follow-up.[](https://pubmed.ncbi.nlm.nih.gov/8804493/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/) Symptom relief with finasteride exhibits a delayed onset, typically requiring 3-6 months for noticeable IPSS reductions, in contrast to alpha-blockers which provide faster symptomatic improvement within weeks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/) Peak flow rate improvements average 1-2 mL/s over placebo, primarily driven by prostate volume reduction.[](https://pubmed.ncbi.nlm.nih.gov/8804493/)\n\nSubgroup analyses indicate finasteride's benefits are most pronounced in men with larger prostates (≥40 mL or \u003e40 g), where RCTs and meta-analyses report significant reductions in symptom progression risk and IPSS (e.g., 3-5 point improvements) compared to placebo, whereas minimal effects occur in those with smaller glands (\u003c40 mL).[](https://pubmed.ncbi.nlm.nih.gov/8804493/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/) In the MTOPS cohort, approximately half of participants had baseline prostate volumes ≥30 mL, aligning with enhanced efficacy in this subset, though overall progression risk reduction held across the trial population.[](https://www.auajournals.org/doi/10.1016/j.juro.2010.11.060) Long-term data from trials like MTOPS and the Proscar Long-term Efficacy and Safety Study (PLESS) confirm sustained reductions in BPH progression and surgical interventions over 4-6 years in eligible patients.[](https://www.nejm.org/doi/full/10.1056/NEJMoa030660) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/)\n\n### Studies on Hair Loss\n\nThe pivotal randomized controlled trials supporting finasteride's approval for androgenetic alopecia involved two 12-month studies of 1 mg daily in men aged 18-41 with mild-to-moderate vertex hair loss, demonstrating a mean increase of 91 hairs per 1 cm² area compared to a loss of 19 hairs in the placebo group.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf) These trials, published in 1998, reported that 48% of finasteride-treated men experienced visible improvement in hair growth versus 7% in the placebo group who showed no further progression of loss.[](https://pubmed.ncbi.nlm.nih.gov/9777765/) A concurrent 1-year study on frontal scalp regions yielded similar results, with finasteride yielding a net hair count gain of approximately 10-15% over baseline.[](https://pubmed.ncbi.nlm.nih.gov/9777765/)\n\nLong-term extensions of these trials, extending to 5 years in over 500 men, confirmed durable scalp hair improvements, with mean hair counts stabilizing or modestly increasing beyond year 2 but plateauing thereafter, indicating maintenance rather than progressive gains.[](https://pubmed.ncbi.nlm.nih.gov/11809594/) In these open-label phases, 65% of participants maintained or improved hair growth at year 5 compared to baseline, versus expected progression in untreated cohorts.[](https://pubmed.ncbi.nlm.nih.gov/11809594/) Meta-analyses of randomized trials affirm finasteride's modest superiority over placebo, with standardized mean differences in hair density favoring treatment by 0.5-1.0 hairs per follicle, though effect sizes diminish after initial response.[](https://pubmed.ncbi.nlm.nih.gov/28396101/)\n\nData on women remain limited to small randomized controlled trials, often using doses of 1-5 mg daily in postmenopausal or normoandrogenic patients with female pattern hair loss.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/) These studies report response rates of 30-50% for increased hair density or halted progression after 6-12 months, but with high variability and smaller sample sizes (n\u003c100 per arm) limiting generalizability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/) A meta-analysis of such trials found statistically significant but clinically modest improvements in hair counts, though efficacy appears lower than in men and inconsistent across subgroups.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/)\n\n### Long-Term Outcomes\n\nIn the Proscar Long-term Efficacy and Safety Study (PLESS), a 4-year randomized, placebo-controlled trial involving 3,040 men with benign prostatic hyperplasia (BPH), finasteride 5 mg daily produced sustained reductions in prostate volume by approximately 18-20% relative to baseline, alongside improvements in urinary symptom scores and maximum flow rates that persisted through the study duration.[](https://pubmed.ncbi.nlm.nih.gov/10510925/) The risk of acute urinary retention (AUR) decreased by 57% in the finasteride group (2.8% incidence) compared to placebo (6.6%), with similar durability in reducing the combined risk of AUR or BPH-related invasive therapy by about 55%.[](https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2008.01785.x) These benefits were most pronounced in men with baseline prostate volumes greater than 40 mL and PSA levels above 1.4 ng/mL, indicating progressive disease stabilization over extended treatment.[](https://pubmed.ncbi.nlm.nih.gov/10510925/)\n\nFor androgenetic alopecia, long-term observational data from a 10-year study of 523 Japanese men treated with finasteride 1 mg daily demonstrated persistent improvements in hair count and subjective assessments, with over 90% of participants maintaining or achieving moderate-to-marked efficacy by global photographic evaluation.[](https://www.oatext.com/Long-term-%2810-year%29-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php) However, discontinuation typically results in reversal of gains, with hair density regressing to pretreatment levels or worse within 6-12 months due to resumption of dihydrotestosterone-driven follicular miniaturization.[](https://emedicine.medscape.com/article/1070167-treatment) Five-year controlled trials similarly confirmed durable scalp hair growth while on therapy, but emphasized the necessity of indefinite use to prevent rebound progression.[](https://www.sciencedirect.com/science/article/pii/S0022202X15529357)\n\nThe Prostate Cancer Prevention Trial (PCPT), a 7-year study of finasteride 5 mg in 18,882 healthy men aged 55 and older, reported a 25% relative reduction in overall prostate cancer prevalence (18.4% in finasteride arm vs. 24.4% placebo), with 18-year follow-up data affirming sustained risk mitigation without excess mortality.[](https://academic.oup.com/jnci/article/99/18/1375/923438) Initial concerns of increased high-grade (Gleason 7-10) tumors (relative risk 1.27) were attributed to detection bias from finasteride's prostate shrinkage and PSA effects rather than true promotion, as subsequent analyses showed no elevation in high-grade risk.[](https://aacrjournals.org/cancerpreventionresearch/article/1/3/174/46398/Finasteride-Does-Not-Increase-the-Risk-of-High) Across indications, the number needed to treat (NNT) for clinically meaningful BPH progression avoidance approximates 14 over 4 years, though benefits must be weighed against prolonged exposure in individual risk profiles.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/)\n\n## Adverse Effects\n\n### Sexual Side Effects\n\nFinasteride, a 5α-reductase inhibitor, is associated with sexual side effects including erectile dysfunction (ED), decreased libido, and ejaculation disorders, primarily due to its suppression of dihydrotestosterone (DHT) levels.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/) A 2019 systematic review and meta-analysis of 15 randomized controlled trials involving 4,495 men treated for androgenetic alopecia (typically with 1 mg/day finasteride) found a relative risk (RR) of 1.66 (95% CI: 1.20–2.30) for overall sexual dysfunction compared to placebo.[](https://pubmed.ncbi.nlm.nih.gov/30206635/) Absolute incidence rates for these effects at 1 mg/day are low, typically 2–4% above placebo levels, with ED reported in approximately 1.3–1.7% of users in long-term studies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/)\n\nAt higher doses used for benign prostatic hyperplasia (5 mg/day), the incidence is elevated. Meta-analyses indicate odds ratios (OR) for ED of 1.47–1.55 (95% CI: 1.14–2.12) and for decreased libido of 1.54 (95% CI: 1.29–1.82) in this context.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/) Reported rates can reach 8–15% for sexual adverse events, compared to 2–4% at 1 mg/day, reflecting dose-dependent DHT suppression (70–80% reduction overall, but more pronounced effects on genital tissues at higher doses).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/) In most cases, these effects are reversible upon discontinuation, though a subset experiences partial or delayed resolution.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/)\n\nThe mechanism involves DHT's role in penile androgen signaling and nitric oxide (NO) production. DHT exhibits higher affinity for androgen receptors than testosterone and more potently upregulates endothelial NO synthase in the corpus cavernosum, facilitating vascular smooth muscle relaxation essential for erection.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/) Finasteride-induced DHT reduction impairs this pathway, decreasing NO bioavailability and promoting oxidative stress, which further disrupts erectile function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/)\n\n### Neuropsychiatric Effects\n\nFinasteride has been associated with neuropsychiatric adverse effects, including depression, anxiety, and suicidal ideation, primarily observed in pharmacovigilance databases and post-marketing reports. Analysis of the WHO VigiBase database identified 395 reports of suicidality and 1,299 reports of depression linked to finasteride use.[](https://pubmed.ncbi.nlm.nih.gov/40473994/) These effects are thought to arise from the drug's inhibition of 5α-reductase, which reduces levels of neuroactive steroids such as allopregnanolone, a positive allosteric modulator of GABA_A receptors that promotes anxiolytic and antidepressant effects.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/) Reduced allopregnanolone impairs GABAergic inhibition, potentially leading to mood dysregulation.[](https://www.mdpi.com/1424-8247/18/7/957)\n\nPharmacovigilance data indicate an upward trend in reported depression and suicidality signals, with a sharp rise in suicidality reports noted in 2024, despite some decline in reporting odds ratios from prior peaks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/) The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets in May 2025, based on disproportionate reporting primarily among users of the 1 mg dose for androgenetic alopecia.[](https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines) [](https://www.medscape.com/viewarticle/ema-decision-finasteride-linked-suicidal-ideation-2025a1000b9x) This acknowledgment followed evaluation of global adverse event data, emphasizing the need for patient monitoring and risk minimization measures, such as informing users of potential mood changes.[](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/)\n\nYounger male users, particularly those under 45 years old treated for hair loss, exhibit a higher relative risk for these effects compared to older populations or those using finasteride for benign prostatic hyperplasia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/) [](https://www.healio.com/news/dermatology/20201203/suicidality-depression-anxiety-higher-in-younger-patients-on-finasteride-for-alopecia) Studies from databases like FAERS have reported three-fold increased likelihood of suicidal ideation or attempts in this demographic, attributed to greater vulnerability to neurosteroid disruptions during peak androgen sensitivity periods.[](https://www.pfsfoundation.org/news/young-men-using-finasteride-for-alopecia-may-be-more-suicide-prone-than-the-general-population-says-new-pharmacovigilance-research/) Empirical evidence from signal detection supports mood-related symptoms like depression and anxiety occurring more frequently in this group, prompting recommendations for baseline psychiatric screening in younger patients.[](https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818)\n\n### Other Physical Effects\n\nFinasteride treatment has been associated with gynecomastia in clinical trials, attributed to an imbalance in the testosterone-to-estradiol ratio resulting from inhibited dihydrotestosterone synthesis and relatively increased aromatization of testosterone to estradiol. In a meta-analysis of 14 studies on 5-alpha reductase inhibitors including finasteride for benign prostatic hyperplasia, gynecomastia occurred in 3.30% of treated patients compared to 1.62% on placebo, yielding an odds ratio of 2.15. For the 1 mg dose used in androgenetic alopecia, incidence is lower, with rates around 0.4% in long-term trials, though case reports document occurrences even after short-term low-dose exposure.[](https://www.sciencedirect.com/science/article/abs/pii/S1526820918308371)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11040274/)\n\nReports of male breast cancer during finasteride therapy are rare but have prompted debate on causality. Up to 2014, approximately 50 cases were reported worldwide with the 5 mg dose and three with 1 mg, against a background rate of male breast cancer of about 1 per 100,000 men annually. A population-based study found a 44% increased risk among finasteride users, potentially linked to hormonal shifts favoring estrogenic effects, though a large case-control analysis reported no material association after confounder adjustment. Regulatory bodies, including the UK's MHRA, have noted the potential risk but emphasize its infrequency, with no definitive causal link established in controlled trials.[](https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancer)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5773955/)[](https://aacrjournals.org/cebp/article/28/5/980/71689/Finasteride-Use-and-Risk-of-Male-Breast-Cancer-A)\n\nFinasteride reduces serum prostate-specific antigen (PSA) levels by approximately 50% within the first 12 months of treatment, necessitating a doubling of measured PSA values for accurate prostate cancer screening to avoid false negatives. This effect persists with continued use and enhances PSA's specificity for detecting high-grade cancers, as observed in the Prostate Cancer Prevention Trial. No consistent evidence links finasteride to adverse metabolic changes, such as insulin resistance or dyslipidemia, or increased cardiovascular events in large cohorts; meta-analyses and trial data show neutral or potentially protective cardiac outcomes in some subgroups, though long-term risks like non-alcoholic fatty liver disease remain under investigation without conclusive signals.[](https://pubmed.ncbi.nlm.nih.gov/16093979/)[](https://academic.oup.com/jnci/article/98/16/1128/2521721)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7308241/)\n\nDermatological reactions, including rash and urticaria, occur in less than 1% of users and are typically mild and reversible upon discontinuation. Case reports describe maculopapular eruptions, psoriasiform reactions, or urticarial rashes emerging weeks to months after initiation, often resolving after drug withdrawal.[](https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/)\n\n## Post-Finasteride Syndrome\n\n### Reported Symptoms and Prevalence\n\nPatients who report post-finasteride syndrome (PFS) describe a cluster of persistent symptoms emerging during finasteride use and enduring for more than three months after discontinuation, including sexual dysfunction such as erectile dysfunction (ED), reduced libido, and orgasmic impairment; neuropsychiatric effects like depression, anxiety, cognitive fog, and memory issues; and physical complaints encompassing chronic fatigue, muscle weakness, and dry skin.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/) In self-selected cohorts of affected individuals, surveys indicate high rates of these symptoms, with 92-94% reporting low libido and ED, alongside 34-49% experiencing anxiety or depression post-discontinuation.[](https://pubmed.ncbi.nlm.nih.gov/21418145/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/)\n\nEmpirical prevalence estimates from retrospective cohort studies suggest persistent sexual symptoms affect approximately 0.8-1.4% of finasteride users, with one analysis of 11,909 exposed men identifying 1.4% developing persistent ED.[](https://www.sciencedirect.com/science/article/pii/S0015028219325993) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/) Self-report registries, such as those maintained by the Post-Finasteride Syndrome Foundation, document over 25,000 worldwide adverse reaction reports linked to finasteride, predominantly involving persistent sexual (e.g., 4,077 ED cases) and psychiatric disorders (e.g., 2,235 depression cases), though these represent voluntary submissions from millions of total users and may reflect selection bias toward severe cases.[](https://www.pfsfoundation.org/pfs-by-the-numbers/) Pharmacovigilance data highlight underreporting in official systems, potentially underestimating true incidence, particularly among younger men treated for hair loss who comprise a disproportionate share of reports.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/)\n\nSymptoms often manifest after cumulative exposure to low doses (e.g., 1 mg daily for androgenetic alopecia), without a defined threshold, and persist variably for months to years in affected individuals, as evidenced by clinical trial follow-ups and patient surveys where dysfunction continued despite cessation.[](https://pubmed.ncbi.nlm.nih.gov/22789024/) Prevalence appears elevated in hair loss treatment cohorts compared to benign prostatic hyperplasia users, possibly due to longer-term, lower-dose regimens or demographic factors like younger age.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5155688/)\n\n### Evidence Supporting Causality\n\nAnimal studies have demonstrated that finasteride withdrawal leads to persistent reductions in neurosteroid levels, particularly allopregnanolone, which modulates GABA_A receptors and influences mood, anxiety, and neuroinflammation.[](https://www.mdpi.com/2218-273X/15/7/1044) In a 2025 preclinical rat model, finasteride administration followed by withdrawal decreased hypothalamic allopregnanolone and induced neuroinflammation, with exogenous allopregnanolone treatment mitigating these effects, suggesting a direct causal link via disrupted neurosteroid signaling.[](https://www.mdpi.com/2218-273X/15/7/1044) Human data corroborate this, showing decreased cerebrospinal fluid allopregnanolone levels persisting after discontinuation in patients reporting PFS symptoms, independent of ongoing 5α-reductase inhibition.[](https://pubmed.ncbi.nlm.nih.gov/36358917/)\n\nEpigenetic mechanisms provide further evidence of causality, as finasteride's inhibition of 5α-reductase alters gene expression through histone modifications and DNA methylation, leading to sustained changes in androgen receptor signaling and neurosteroid pathways.32599-3/fulltext) A 2024 study on human Leydig cells exposed to finasteride revealed epigenetic modifications in dopaminergic pathways, with differential gene expression observed in PFS patients compared to controls, indicating drug-induced transcriptional reprogramming as a persistent driver of symptoms.[](https://journals.physiology.org/doi/abs/10.1152/physiol.2024.39.S1.1269)[](https://www.researchgate.net/publication/353127752_Differential_Gene_Expression_in_Post-Finasteride_Syndrome_Patients)\n\nAdverse drug reaction databases highlight temporal associations supporting causality, with VigiBase reporting disproportionate increases in finasteride-linked suicidality and self-injurious behaviors; for instance, suicidal ideation rose 4.2% and suicide attempts 3.7% in recent analyses, exceeding expected rates for the drug class.[](https://www.pfsfoundation.org/news/finasteride-induced-suicides-up-8-4-in-whos-vigibase/)\n\nCohort investigations identify biomarkers correlating with persistent symptoms in 1-2% of users, including altered steroid profiles and gut microbiota dysbiosis post-withdrawal.[](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309849) A 2025 cohort study using fMRI detected abnormal brain activity in emotion-regulation regions among PFS patients without prior psychiatric history, alongside persistent neurosteroid imbalances.[](https://www.pfsnetwork.org/science/y77lkfbdtqfnn42n5n9cvjzdqmsjd1-IZCIP) Genetic factors, such as shorter CAG repeats in the androgen receptor gene, increase susceptibility to these persistent effects by enhancing receptor sensitivity to disrupted steroid environments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/)\n\n### Counterarguments and Alternative Explanations\n\nCritics of post-finasteride syndrome (PFS) causality emphasize the nocebo effect, wherein awareness of potential side effects generates or amplifies symptoms through negative expectations. Placebo-controlled trials of finasteride for androgenetic alopecia reported sexual adverse events at rates comparable to placebo (e.g., 1.8% vs. 1.3% for decreased libido in pivotal studies), indicating that expectation bias, rather than direct pharmacology, may drive perceived persistence.[](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972) [](https://pubmed.ncbi.nlm.nih.gov/21418145/)\n\nA 2024 review in *Translational Andrology and Urology* by Carson et al. argues that PFS lacks substantiation as a distinct entity, attributing reports to unproven mechanisms amid insufficient blinded, prospective evidence linking finasteride cessation to enduring symptoms; the authors highlight that randomized data show effects as \"minimal and fleeting\" for most users, challenging claims of irreversibility.[](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972)\n\nPre-existing vulnerabilities among finasteride users, particularly those pursuing treatment for cosmetic hair loss, may confound attributions to the drug; such individuals often exhibit elevated baseline risks for anxiety, depression, or sexual dissatisfaction, potentially amplifying subjective complaints unrelated to 5α-reductase inhibition.[](https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243) A 2025 analysis reframes PFS symptoms as manifestations of selection bias in patient cohorts prone to psychological distress from appearance concerns, rather than novel drug-induced pathology.[](https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243)\n\nMethodological flaws in PFS literature, including reliance on self-selected online surveys from advocacy forums, inflate prevalence estimates by excluding asymptomatic users and lacking validated controls or objective biomarkers; these designs fail to differentiate drug effects from regression to baseline or unrelated comorbidities.[](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972) [](https://www.sciencedirect.com/science/article/pii/S235228951930061X)\n\nIn manufacturer-sponsored trials, sexual side effects resolved in over 95% of cases upon discontinuation, with long-term follow-up (up to 5 years) showing no excess persistence beyond placebo rates, supporting reversibility as the norm rather than exception.[](https://pubmed.ncbi.nlm.nih.gov/21418145/) [](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972)\n\nRegulatory assessments align with skepticism: the U.S. FDA, in its June 2022 response to a citizen petition, denied requests for enhanced labeling or market withdrawal, concluding the submitted evidence failed to establish reasonable causality for persistent effects beyond known, transient risks.[](https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf)\n\n### Regulatory and Legal Responses\n\nIn April 2025, the U.S. Food and Drug Administration (FDA) issued an alert to health care providers, compounders, and consumers about potential serious risks from compounded topical finasteride products, which lack FDA-approved labeling and established safety profiles; this followed 32 adverse event reports submitted to the FDA Adverse Event Reporting System between 2019 and 2024.[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded)[](https://www.dermatologyadvisor.com/news/concerns-over-compounded-topical-finasteride-prompt-fda-alert/)\n\nIn May 2025, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as an adverse reaction to finasteride 1 mg and 5 mg tablets, primarily reported in users treating androgenetic alopecia; the committee recommended risk minimization measures, including updated product information to warn of psychiatric effects and enhanced patient monitoring, while noting most cases resolved upon discontinuation but acknowledging potential persistence in some instances.[](https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines)[](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025)\n\nMultiple class-action lawsuits have targeted Merck, the maker of Propecia (finasteride 1 mg), claiming the company underreported risks of post-finasteride syndrome, including persistent neuropsychiatric harms linked to suicides, despite post-marketing data suggesting higher incidence than clinical trials indicated.[](https://www.drugwatch.com/propecia/lawsuits/) In ongoing 2025 Propecia litigation, expert witness testimony estimated hundreds to thousands of suicides attributable to finasteride-induced effects, based on pharmacovigilance analyses and underreporting factors, highlighting tensions between regulatory assurances of rarity and aggregated patient reports exceeding expected baselines.[](https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/) These cases, including a 2021 suit by the Post-Finasteride Syndrome Foundation against the FDA for alleged inaction on labeling petitions, underscore discrepancies where agency positions have lagged behind litigation-revealed evidence volumes.[](https://www.citizen.org/news/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia/)\n\n## Safety Profile and Risk-Benefit Analysis\n\n### Dose-Dependent Risks\n\nThe incidence of adverse effects from finasteride exhibits dose dependence, with higher absolute risks at the 5 mg daily dose used for benign prostatic hyperplasia compared to the 1 mg dose for androgenetic alopecia. In pivotal trials, sexual side effects such as erectile dysfunction occurred in 8.1% of men on 5 mg versus 3.7% on placebo, while for 1 mg, the rate was 1.8% versus 1.1% on placebo.  Relative risks for sexual dysfunction remain elevated across doses, though absolute event rates are lower at 1 mg due to reduced systemic DHT inhibition (approximately 65-70% scalp DHT reduction at 1 mg versus near-complete at 5 mg).[](https://pubmed.ncbi.nlm.nih.gov/10495375/)\n\nMeta-analyses from 2018 to 2023 confirm a dose-independent relative risk elevation for adverse sexual effects, with 5α-reductase inhibitors including finasteride associated with a 1.57-fold increased risk (95% CI 1.19–2.08) of any sexual dysfunction versus placebo, irrespective of indication. Subgroup analysis for finasteride 1 mg yielded a 1.66-fold risk (95% CI 1.20–2.30), driven primarily by erectile dysfunction and decreased libido, while 5 mg showed comparable relative but higher absolute risks in prostate trials.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9295476/) [](https://pubmed.ncbi.nlm.nih.gov/30206635/)\n\nDuration of exposure contributes to risk scaling, with cumulative use exceeding 1 year linked to heightened odds of persistent effects post-discontinuation; in cohorts with mean exposure of 28 months, over 90% of those developing side effects lasting ≥3 months experienced continuation for years.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/) No established safe threshold exists, as even low-dose, short-term use reports rare persistence in sensitive individuals.\n\nIndividual factors modulate dose-dependent risks: younger age (\u003c40 years) correlates with greater persistence likelihood, potentially due to neurosteroid disruption during peak androgen sensitivity, while genetic variants in androgen receptor or steroid metabolism genes (e.g., SRD5A2 polymorphisms) may predispose subsets to amplified effects, suggesting pharmacogenomic screening for high-risk patients. [](https://pubmed.ncbi.nlm.nih.gov/36386264/)\n\n### Topical vs. Oral Formulations\n\nTopical finasteride formulations are promoted for reducing dihydrotestosterone (DHT) primarily at the scalp site of application, with proponents claiming minimized systemic exposure compared to oral administration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/) Clinical trials have demonstrated that topical finasteride achieves scalp DHT reductions of 68-75%, comparable to 62-72% with oral finasteride, while exhibiting lower plasma finasteride concentrations and serum DHT suppression (e.g., 34.5% reduction versus 55.6% for oral).[](https://www.ishrs-htforum.org/content/28/3/112)[](https://perfecthairhealth.com/does-topical-finasteride-work/) This localized targeting is intended to preserve efficacy against androgenetic alopecia while attenuating body-wide hormonal effects.[](https://pubmed.ncbi.nlm.nih.gov/34634163/)\n\nHowever, systemic absorption occurs via transdermal routes, leading to detectable serum DHT changes and potential adverse events akin to oral use.[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded) In April 2025, the U.S. Food and Drug Administration (FDA) issued an alert regarding compounded topical finasteride products, citing reports of serious risks including erectile dysfunction, depression, anxiety, suicidal ideation, and decreased libido—symptoms consistent with finasteride's known profile despite topical delivery.[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded) These events underscore bioavailability challenges, as skin absorption bypasses first-pass hepatic metabolism and varies with factors like formulation, application site, and individual skin permeability.[](https://onlinelibrary.wiley.com/doi/10.1111/ijd.17957)\n\nCompounded topical preparations introduce additional risks from dosing inconsistencies and quality variability, lacking standardized manufacturing controls of approved oral forms.[](https://nabp.pharmacy/news/blog/regulatory_news/compounded-topical-finasteride-products-associated-with-serious-risks/) Pharmacokinetic analyses indicate that while average systemic exposure is reduced, inter-patient absorption differences can result in unintended elevations in circulating finasteride levels, potentially negating safety advantages.[](https://www.ijbamr.com/assets/images/issues/pdf/71nag2_6w0c1i_34kUVI_YI8x3j_177107.pdf)\n\nRegarding post-finasteride syndrome (PFS), topical formulations show fewer adverse event signals resembling PFS compared to oral in pharmacovigilance data, but cases have been documented, and no controlled evidence confirms prevention.[](https://pubmed.ncbi.nlm.nih.gov/40662444/)[](https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/) Long-term studies are absent, leaving causality and risk mitigation unestablished for persistent symptoms.[](https://hcplive.com/view/study-compares-safety-findings-oral-versus-topical-finasteride-for-alopecia)\n\n### Interactions and Overdose\n\nFinasteride is primarily metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system, and inhibitors of this enzyme, such as ketoconazole, can increase its plasma concentrations and prolong its half-life by reducing clearance.[](https://go.drugbank.com/drugs/DB01216) [](https://www.ncbi.nlm.nih.gov/books/NBK513329/) Inducers of CYP3A4, like rifampin, may decrease finasteride levels, though clinical significance remains limited based on available data.[](https://reference.medscape.com/drug/propecia-proscar-finasteride-342824) No clinically meaningful interactions with food have been observed, as bioavailability is approximately 65% regardless of administration with or without meals.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) Concomitant use with testosterone replacement therapy warrants caution, as finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT), potentially altering androgen profiles, though studies indicate compatibility without prohibitive risks in monitored settings.[](https://www.endocrine-abstracts.org/ea/0021/ea0021p43)\n\nFor prostate cancer screening, finasteride reduces serum prostate-specific antigen (PSA) levels by about 50% after 6–12 months of use, requiring clinicians to double observed PSA values to interpret results accurately and avoid under-detection of prostate abnormalities.[](https://pubmed.ncbi.nlm.nih.gov/16093979/) [](https://www.urologytimes.com/view/psa-adjustments-are-required-men-taking-5-aris)\n\nOverdose with finasteride is rare and typically non-life-threatening due to its wide therapeutic index. In animal toxicity studies, the oral median lethal dose (LD50) in rats is approximately 418 mg/kg.[](https://go.drugbank.com/drugs/DB01216) Human data from single doses up to 400 mg and repeated doses of 80 mg daily for three months show no serious adverse effects, with any symptoms—such as transient increases in serum testosterone due to inhibited 5α-reductase activity—being reversible upon discontinuation.[](https://go.drugbank.com/drugs/DB01216) No fatalities attributable to finasteride overdose have been documented, and management involves supportive care without specific antidotes.[](https://go.drugbank.com/drugs/DB01216)\n\n## History and Development\n\n### Discovery and Approval\n\nFinasteride, a synthetic 4-azasteroid compound, was developed by Merck \u0026 Co. in the 1980s as a selective inhibitor of type II 5α-reductase, an enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in androgen-dependent tissues such as the prostate. Initially pursued to address prostate disorders by reducing DHT-mediated prostate enlargement and associated urinary symptoms in benign prostatic hyperplasia (BPH), the drug's development leveraged early research identifying 5α-reductase as a therapeutic target for such conditions. Merck patented finasteride in 1984, focusing on its potency and tissue selectivity to minimize off-target effects.[](https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/)[](https://pubmed.ncbi.nlm.nih.gov/15992088/)\n\nThe U.S. Food and Drug Administration (FDA) approved finasteride 5 mg tablets under the brand name Proscar on June 19, 1992, for the treatment of symptomatic BPH in men, marking the first regulatory milestone for a 5α-reductase inhibitor in this indication. This approval was based on clinical data demonstrating reductions in prostate volume and improvements in urinary flow rates. Similar authorizations followed in the European Union shortly thereafter, with national agencies granting marketing approval for Proscar equivalents in the early 1990s to manage BPH symptoms.[](https://insights.citeline.com/PS021070/MERCKs-PROSCAR-FINASTERIDE-APPROVED-JUNE-19-AFTER-14MONTH-REVIEW/)[](https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf)\n\nRegulatory expansion to hair loss occurred through serendipitous findings during BPH studies, where participants exhibited reduced scalp DHT levels and hair regrowth, prompting investigation of lower doses for androgenetic alopecia. The FDA approved finasteride 1 mg tablets as Propecia on December 19, 1997, specifically for male pattern baldness in men aged 18-41, supported by trials showing sustained hair count increases over two years. European approvals for the 1 mg formulation trailed slightly, occurring in 1998-1999 across member states.[](https://conexiant.com/dermatology/articles/fda-warns-of-topical-finasteride-risks/)[](https://upguys.com/blog/finasteride-mechanism-of-action)[](https://finasterideinfo.org/regulation/)\n\n### Key Clinical Trials\n\nThe pivotal phase III clinical trials for finasteride in benign prostatic hyperplasia (BPH) were conducted in the early 1990s and formed the basis for its approval as Proscar at a 5 mg daily dose by the U.S. Food and Drug Administration in June 1992. A multicenter, double-blind, placebo-controlled study involving 3,040 men with symptomatic BPH demonstrated that 5 mg finasteride daily for 12 months significantly reduced prostate volume by approximately 19% compared to placebo, improved urinary flow rates by 1.6 mL/s, and alleviated obstructive symptoms, with these benefits persisting in long-term extensions up to four years.[](https://www.nejm.org/doi/full/10.1056/NEJM199210223271701) [](https://pubmed.ncbi.nlm.nih.gov/7505970/)\n\nThe Prostate Cancer Prevention Trial (PCPT), a large-scale, randomized, double-blind, placebo-controlled study published in 2003, evaluated 5 mg finasteride daily in 18,882 men aged 55 or older with normal prostate-specific antigen (PSA) levels and digital rectal exams. Over seven years, finasteride reduced overall prostate cancer prevalence by 24.8% (803 cases in the finasteride group versus 1,147 in placebo), but an increased detection of high-grade (Gleason score 7-10) tumors raised concerns about potential promotion of aggressive disease, though subsequent analyses debated whether this reflected detection bias from prostate volume reduction rather than true carcinogenesis.[](https://www.nejm.org/doi/full/10.1056/NEJMoa030660) [](https://www.nejm.org/doi/full/10.1056/NEJMoa1215932)\n\nFor androgenetic alopecia, dose-ranging randomized controlled trials (RCTs) in the 1990s established 1 mg daily as optimal, leading to approval as Propecia in December 1997. These studies, involving men aged 18-41 with mild to moderate vertex or frontal hair loss, showed that 1 mg finasteride increased scalp hair count by 10-15% over one year versus placebo, with maximal dihydrotestosterone suppression in scalp tissue at doses as low as 0.2 mg but superior efficacy at 1 mg for hair regrowth and halting progression over two years; higher doses like 5 mg offered no additional benefit for hair while risking greater systemic effects.[](https://pubmed.ncbi.nlm.nih.gov/10495375/) [](https://www.jaad.org/article/S0190-9622%2898%2970007-6/abstract) Large-scale RCTs for female pattern hair loss were absent during this period, with early investigations limited to off-label use and smaller cohorts showing inconsistent results until the 2010s.[](https://www.sciencedirect.com/science/article/pii/S0365059623000533)\n\n### Evolution of Indications\n\nFinasteride received initial U.S. Food and Drug Administration (FDA) approval in June 1992 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men, marketed as Proscar at a 5 mg daily dose to reduce prostate volume and alleviate urinary symptoms.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) This indication stemmed from clinical trials demonstrating its inhibition of 5α-reductase, which lowers dihydrotestosterone levels and shrinks enlarged prostates.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf) By the mid-1990s, its application expanded to male androgenetic alopecia following Merck's development of a 1 mg formulation.\n\nIn December 1997, the FDA approved finasteride at 1 mg daily (Propecia) specifically for male pattern hair loss, marking a shift toward dermatological use driven by pivotal trials showing sustained hair count increases over five years in 65% of treated men versus placebo.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/) This lower-dose approval broadened accessibility, particularly among younger men, where alopecia prescriptions soon dominated over BPH uses due to the condition's prevalence—affecting up to 50% of men over 50—and finasteride's efficacy in stabilizing vertex and anterior mid-scalp hair loss.[](https://www.sciencedirect.com/science/article/pii/S0022202X15529357) By the 2000s, hair loss treatment accounted for the majority of prescriptions, reflecting a pivot from urological to cosmetic applications despite the original BPH focus.[](https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961690-X/fulltext)\n\nExploration for prostate cancer prevention via the Prostate Cancer Prevention Trial (PCPT, 1993–2003) revealed a 24.8% overall risk reduction but a higher incidence of high-grade (Gleason 8–10) tumors (1.8% versus 1.1% placebo), prompting no approval and label revisions in 2009–2011 to warn of potential high-grade cancer risk.[](https://www.nejm.org/doi/full/10.1056/NEJMoa1215932)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf) Subsequent analyses suggested detection bias from finasteride's prostate shrinkage and PSA effects may have inflated high-grade detections without elevating mortality, yet regulatory caution precluded preventive labeling.[](https://pubmed.ncbi.nlm.nih.gov/17848673/)\n\nOff-label uses emerged in the 2010s, including for hirsutism in women with polycystic ovary syndrome or idiopathic causes, where randomized trials reported over 50% reductions in hirsutism scores at 5 mg doses, though without FDA endorsement due to teratogenic risks and limited large-scale data.[](https://pubmed.ncbi.nlm.nih.gov/30604525/)[](https://www.sciencedirect.com/science/article/pii/S0015028216583885) Post-2020, topical formulations gained traction for alopecia to minimize systemic exposure, supported by smaller studies showing comparable efficacy to oral versions with potentially fewer side effects, but no new FDA indications materialized; compounded topicals remain unapproved, with 2025 alerts citing absorption risks and adverse event reports.[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded) Evidence gaps persist for long-term off-label safety, particularly in women and non-approved routes, limiting formal expansions beyond core urological and dermatological roles.[](https://www.ncbi.nlm.nih.gov/books/NBK513329/)\n\n## Society and Culture\n\n### Branding, Generics, and Availability\n\nFinasteride is marketed under the brand name **Proscar** (5 mg tablets) for the treatment of benign prostatic hyperplasia and **Propecia** (1 mg tablets) for male pattern hair loss, both developed by Merck \u0026 Co.[](https://www.drugs.com/finasteride.html) [](https://www.webmd.com/drugs/2/drug-1548-167/finasteride-oral/finasteride-oral/details) Generic versions of finasteride in both 1 mg and 5 mg strengths became widely available following patent expirations; in the United States, the patent for Propecia expired in 2013, with the first generic approvals occurring on November 5, 2013, by manufacturers such as Accord Healthcare.[](https://www.drugs.com/availability/generic-propecia.html) [](https://www.drugpatentwatch.com/p/generic-api/FINASTERIDE)\n\nThe entry of generics led to substantial price reductions, often exceeding 80% compared to branded versions, enhancing affordability and access for patients in regulated markets.[](https://www.drugpatentwatch.com/p/drug-price/drugname/FINASTERIDE) [](https://www.doctorfox.co.uk/news/patent-for-propecia-expires-in-the-uk/) For instance, generic finasteride 1 mg tablets, which retailed for around $100–$150 monthly for branded Propecia pre-expiry, dropped to $10–$20 per month post-2013 in the US, depending on pharmacy and quantity.[](https://www.goodrx.com/finasteride) Efforts to reclassify finasteride for over-the-counter sale, particularly for lower-dose hair loss treatment, have not succeeded in major jurisdictions due to concerns over side effects, including sexual dysfunction and teratogenic risks, maintaining its prescription-only status with mandatory patient information on handling and contraception.[](https://www.hims.com/blog/is-finasteride-over-the-counter) [](https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819)\n\nGlobally, finasteride is accessible in over 100 countries through approved pharmaceutical channels, with formulations authorized by bodies such as the European Medicines Agency for both oral and topical uses in men.[](https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products) Availability varies by regulatory framework—prescription-required in the US, EU, UK, Canada, and Australia—but is broadly permitted except where stringent pregnancy contraindications limit distribution or require specialized handling protocols, as the drug causes genital abnormalities in male fetuses if handled by pregnant women.[](https://www.drugs.com/pregnancy/finasteride.html) [](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf) In developing regions, generics dominate supply chains, further driving down costs amid growing market demand projected to reach USD 4.6 billion by 2035.[](https://www.researchnester.com/reports/finasteride-market/2984)\n\n### Use in Athletics and Doping\n\nFinasteride, a 5α-reductase inhibitor, was added to the World Anti-Doping Agency (WADA) Prohibited List in 2005 as a masking agent capable of altering urinary steroid profiles to evade detection of exogenous anabolic-androgenic steroids, such as nandrolone and its precursors.[](https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2005_EN.pdf)[](https://www.wada-ama.org/en/resources/scientific-research/investigation-about-deffects-and-detection-finasteride-substance) This inclusion stemmed from research demonstrating that finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT), thereby modifying metabolite ratios like the testosterone/epitestosterone (T/E) ratio and nandrolone indicators, which are used in doping controls.[](https://pubmed.ncbi.nlm.nih.gov/17417080/) Initial temporary therapeutic use exemptions (TUEs) for medical conditions like benign prostatic hyperplasia or androgenetic alopecia were permitted but phased out as WADA prioritized uniform enforcement, with exemptions ending by 2006 for non-essential uses.[](https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/)\n\nThe prohibition lacked evidence of direct ergogenic (performance-enhancing) effects from finasteride alone, as its primary action reduces DHT without substantially elevating free testosterone levels or anabolic signaling in skeletal muscle.[](https://pubmed.ncbi.nlm.nih.gov/34318592/) DHT, derived from testosterone via 5α-reductase, plays a minor role in muscle hypertrophy compared to testosterone, and finasteride's suppression (up to 70% in serum) has shown no significant impact on strength, endurance, or recovery in controlled studies of healthy males.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4073894/) Speculation on indirect effects, such as altered muscle repair via DHT's androgen receptor affinity in prostate or skin tissues, remains unsubstantiated for athletic contexts, with empirical data indicating neutral outcomes on body composition or exercise capacity.[](https://pubmed.ncbi.nlm.nih.gov/17417080/)\n\nDoping violations involving finasteride were rare and typically unintentional, linked to its prescription for hair loss rather than deliberate enhancement. Notable cases include U.S. skeleton racer Zach Lund, who tested positive in 2005 after using it for alopecia and received a temporary ban despite appealing for a retroactive TUE, and Brazilian footballer Romário, sanctioned in 2006 for similar therapeutic use.[](https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/)[](https://pubmed.ncbi.nlm.nih.gov/17417080/) WADA required athletes to apply for TUEs via national anti-doping organizations during the ban, with denials triggering mandatory notifications to international federations and potential suspensions; approval rates were low absent compelling medical necessity.[](https://www.wada-ama.org/en/athletes-support-personnel/therapeutic-use-exemptions-tues)\n\nIn 2009, WADA removed finasteride from the Prohibited List following refinements in gas chromatography-mass spectrometry techniques that adjusted for its metabolic interference, rendering masking ineffective without compromising test specificity.[](https://www.abc.net.au/news/2008-10-28/hair-loss-drug-wiped-from-doping-banned-list/184554)[](https://pubmed.ncbi.nlm.nih.gov/34318592/) As of 2025, it remains unprohibited in and out of competition, with no resurgence in doping concerns due to advanced biomarker profiling.[](https://www.wada-ama.org/en/prohibited-list)\n\n### Public Perception and Controversies\n\nFinasteride's use for male pattern baldness has often been stigmatized as a vanity treatment, reflecting broader societal discomfort with men addressing cosmetic hair loss through medication rather than accepting it as natural aging. This perception persists despite surveys indicating that up to 70% of men experience some degree of baldness-related self-consciousness, with cultural ideals of youth and vitality amplifying pressures on male body image.[](https://www.bbc.com/news/health-44052917) Critics argue that promoting finasteride for non-life-threatening conditions like androgenetic alopecia exemplifies over-medicalization, prioritizing appearance enhancement over potential risks in otherwise healthy individuals.[](https://onlinelibrary.wiley.com/doi/10.1111/dth.12647)\n\nOnline forums dedicated to post-finasteride syndrome (PFS) have significantly shaped public discourse, raising awareness of persistent side effects while sometimes fueling alarmism through anecdotal reports and unverified claims. Communities such as those hosted by the PFS Foundation have highlighted cases of severe psychological distress, with an expert witness in 2025 litigation estimating that hundreds to thousands of men may have died by suicide due to PFS-related effects since the drug's approval.[](https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/) These platforms contrast with pharmaceutical defenses, including Merck's historical downplaying of risks, as alleged in lawsuits and investigations revealing suppressed trial data on persistent sexual and mood issues.[](https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/)\n\nMedia coverage in 2025 intensified scrutiny following regulatory actions, with the European Medicines Agency confirming suicidal ideation as a side effect of finasteride tablets in May, prompting updated warnings and patient alert cards.[](https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines) Outlets like CBC and the New York Post amplified patient testimonies of debilitating effects, shifting narratives from routine safety endorsements to calls for caution, particularly for younger users treating hair loss.[](https://www.cbc.ca/news/health/hair-loss-drug-finasteride-side-effects-1.7483898)[](https://nypost.com/2025/10/08/health/hair-loss-treatment-used-by-millions-linked-to-suicide-risk/) This evolution highlights tensions between advocacy groups pushing for black-box warnings and industry responses emphasizing rarity of events, amid accusations of regulatory delays in acknowledging neuropsychiatric links.[](https://www.medicalbrief.co.za/fda-merck-accused-of-covering-up-hair-loss-pills-suicide-link/)\n\n## Ongoing Research\n\n### Recent Developments (2024-2025)\n\nIn April 2025, the U.S. Food and Drug Administration (FDA) issued an alert regarding potential risks associated with compounded topical finasteride products, which lack FDA approval for any topical formulation. The agency reported 32 adverse drug reactions (ADRs) over the preceding five years, including erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido, and testicular pain, emphasizing risks from inconsistent compounding practices and variable absorption.[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded)[](https://www.consumermedsafety.org/safety-articles/risks-of-topical-finasteride)\n\nIn May 2025, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets following an EU-wide review, implementing new risk mitigation measures such as updated product information to advise patients on monitoring for psychiatric symptoms. No direct causal link was established for dutasteride, though both drugs carry known psychiatric risks. These updates built on prior signals without altering overall benefit-risk profiles.[](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025)[](https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf)\n\nAnalyses of global pharmacovigilance databases in 2025 highlighted surges in reported finasteride-related ADRs, including a reported 10,000% week-over-week increase in WHO VigiBase entries early in the year, surpassing 2024 records by 42% and incorporating 119 new suicidality cases. Concurrent studies linked these effects to finasteride's inhibition of 5α-reductase, which suppresses neurosteroid synthesis like allopregnanolone, potentially dysregulating mood via serotonergic pathways.[](https://www.pfsfoundation.org/news/finasteride-adrs-soar-10000-week-over-week-says-world-health-organization/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/)[](https://www.sciencedaily.com/releases/2025/10/251013040343.htm)\n\nLitigation involving Propecia (finasteride 1 mg) intensified in 2025, with lawsuits alleging underreporting of persistent neuropsychiatric effects; expert testimony in federal cases estimated hundreds to thousands of unreported suicides attributable to post-finasteride syndrome, prompting calls for systematic evidence reviews on causality. These claims, drawn from real-world adverse event data, underscore ongoing debates over long-term risk disclosure.[](https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/)\n\n### Emerging Therapies and Alternatives\n\nDutasteride, a dual inhibitor of type I and II 5α-reductase enzymes, achieves greater dihydrotestosterone (DHT) suppression (98% serum reduction) compared to finasteride's 71%, leading to superior hair regrowth in androgenetic alopecia trials, with thrice-weekly dosing showing moderate-to-marked improvement in 35% of patients versus 21% for daily finasteride.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9561294/)[](https://www.jaadinternational.org/article/S2666-3287%2825%2900101-4/fulltext) However, it carries comparable or elevated risks of sexual dysfunction and breast tenderness, with no demonstrated reduction in prostate cancer risk relative to finasteride in benign prostatic hyperplasia cohorts.[](https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327)[](https://www.innerbody.com/dutasteride-vs-finasteride)\n\nTopical formulations combining finasteride (0.25%) with minoxidil (5%) demonstrate enhanced efficacy over minoxidil monotherapy in male pattern hair loss, yielding significant improvements in hair density and diameter in 90% of users, potentially mitigating systemic absorption and side effects associated with oral administration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12537375/)[](https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/) Systematic reviews confirm synergistic effects, though long-term safety data remain preliminary amid reports of adverse events with compounded topicals.[](https://www.healio.com/news/dermatology/20241205/topical-finasteride-minoxidil-combination-efficacious-in-male-androgenic-alopecia)[](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded)\n\nPlatelet-rich plasma (PRP) injections emerge as a non-pharmacological adjunct for androgenetic alopecia, stimulating follicular regeneration via growth factors with minimal side effects and efficacy comparable to or exceeding finasteride in density gains, positioning it as a viable alternative for patients averse to hormonal modulation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216252/)[](https://scandinavianbiolabs.com/blogs/hair-loss/prp-vs-finasteride) Prospective comparisons indicate PRP's adjuvant role with minoxidil yields better outcomes than finasteride-fortified topicals in some metrics, though optimal protocols require further standardization.[](https://ijced.org/archive/volume/8/issue/2/article/7808)\n\nGenetic screening for variants in SRD5A1 and SRD5A2 genes shows preliminary associations with treatment response, enabling prediction of non-responders to 5α-reductase inhibitors and guiding personalized selection between finasteride and dutasteride.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6746394/)[](https://perfecthairhealth.com/srd5a1-2-can-these-genes-predict-regrowth-from-5-alpha-reductase-inhibitors/) Studies link specific polymorphisms to differential DHT metabolism and regrowth potential, though clinical utility awaits larger validation beyond niche pharmacogenetic tests.[](https://www.albareyes.com/genetic-tests/genetic-tests-for-finasteride-response/)\n\nFor post-finasteride syndrome, no proven therapies exist as of 2024, with ongoing monitoring of investigational agents by advocacy groups but limited empirical support for neurosteroid or gene-based interventions.[](https://www.pfsfoundation.org/research/)[](https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972) Causal mechanisms remain debated, emphasizing pre-treatment genetic evaluation to identify vulnerability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641066/)"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761885329134,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"[PDF] PROPECIA (finasteride) tablets - accessdata.fda.gov\",\"description\":\"12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Finasteride is a competitive and specific inhibitor of Type II 5α-reductase, an intracellular enzyme that.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Finasteride - StatPearls - NCBI Bookshelf\",\"description\":\"Feb 28, 2024 · Finasteride is an FDA-approved pharmacologic agent for treating benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men.Continuing Education Activity · Mechanism of Action · Administration · Monitoring\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK513329/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"[PDF] Propecia (finasteride) - accessdata.fda.gov\",\"description\":\"Generic Name: finasteride. Sponsor: Merck Sharp \u0026 Dohme Corp. Approval Date: March 11, 2011. Labeling. Changes: Addition of depression to the post-marketing.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Court let Merck hide secrets about baldness drug's risks - CNBC\",\"description\":\"Sep 11, 2019 · Merck initially obtained FDA approval in 1992 to market finasteride in a five-milligram pill called Proscar to treat enlarged prostate.\",\"url\":\"https://www.cnbc.com/2019/09/11/court-let-merck-hide-secrets-about-baldness-drugs-risks.html\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Finasteride in the treatment of patients with benign prostatic ... - NIH\",\"description\":\"Finasteride represents a cost-effective means of reducing BPH progression and its complications in men with enlarged prostates \u003e30 cm 3.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2710385/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Efficacy of finasteride is maintained in patients with benign prostatic ...\",\"description\":\"Patients treated with finasteride 5 mg maintained an initial decrease in prostate volume and improvement in symptom score and maximal urinary flow rate over 5 ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0090429598006669\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Finasteride: a review of its use in male pattern hair loss - PubMed\",\"description\":\"The 5alpha-reductase inhibitor finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for male pattern ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9951956/\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Finasteride and Dutasteride for the Treatment of Male Androgenetic ...\",\"description\":\"Oct 27, 2023 · Both finasteride and dutasteride are effective at treating hair loss in male AGA, with studies finding dutasteride is more efficacious than finasteride.\",\"url\":\"https://gmr.scholasticahq.com/article/88531-finasteride-and-dutasteride-for-the-treatment-of-male-androgenetic-alopecia-a-review-of-efficacy-and-reproductive-adverse-effect\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Finasteride and sexual side effects - PMC - NIH\",\"description\":\"Finasteride, a 5-alpha reductase inhibitor, widely used in the medical management of male pattern hairloss, has been reported to cause sexual side effects.Missing:  pharmacology | Show results with:pharmacology\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Post-finasteride syndrome: An emerging clinical problem\",\"description\":\"This condition, termed post-finasteride syndrome (PFS) is characterized by sexual side effects (ie, low libido, erectile dysfunction, decreased arousal and ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S235228951930061X\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Post‐finasteride syndrome: real or myth? - Carson - 2024\",\"description\":\"Jun 18, 2024 · Men who report persistent sexual, neurological, and psychological side-effects after discontinuing finasteride are said to have ...Abstract · 5ARI drugs and men's health · Proposed aetiology of post...\",\"url\":\"https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/tre.972\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Post-finasteride syndrome: a surmountable challenge for clinicians\",\"description\":\"Jan 29, 2020 · Reduced volume of ejaculate, erectile dysfunction, loss of libido, and gynecomastia was more common in the finasteride group than in the placebo ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0015028219325993\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Comparison of Finasteride and Dutasteride on Risk of Prostate ...\",\"description\":\"May 20, 2024 · A recent meta-analysis suggested that finasteride should be administered for at least 4 years to prevent prostate cancer [9]. In addition ...\",\"url\":\"https://wjmh.org/DOIx.php?id=10.5534/wjmh.230327\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"5α-Reductase Inhibitors - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Jun 8, 2024 · The 5α-reductase inhibitors (finasteride and dutasteride) are effective treatments for both BPH and androgenic alopecia. Given the longer ...Missing:  pharmacology | Show results with:pharmacology\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK555930/\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Finasteride: The First 5α‐Reductase Inhibitor - ACCP Journals - Wiley\",\"description\":\"Finasteride is a synthetic 4-azasteroid that is a specific competitive inhibitor of 5α-reductase, an intracellular enzyme that converts testosterone to ...Missing:  pharmacodynamics mechanism\",\"url\":\"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.1993.tb02739.x\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"5-alpha reductase inhibitors use in prostatic disease and beyond\",\"description\":\"Mar 31, 2023 · Finasteride reduced prostate volume by 18% compared to a 14% increase in the place group. Similarly, dutasteride has comparable results with a ...\",\"url\":\"https://tau.amegroups.org/article/view/111026/html\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"[PDF] PROPECIA® - accessdata.fda.gov\",\"description\":\"Inhibition of Type II 5α-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788Orig1s022lbl.pdf\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"The Dark Side of 5α-Reductase Inhibitors' Therapy - PubMed Central\",\"description\":\"Jun 16, 2014 · Finasteride treatment resulted in decreased levels of 5α-DHT and 3α, 5α-tetrahydroprogesterone (AP) and increased levels of testosterone ...Missing:  signaling | Show results with:signaling\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4064044/\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Effects of Subchronic Finasteride Treatment and Withdrawal on ...\",\"description\":\"Dec 9, 2015 · In summary, our findings indicate that finasteride treatment causes modifications in the levels of neuroactive steroids and their receptors in ...\",\"url\":\"https://karger.com/nen/article/103/6/746/220377/Effects-of-Subchronic-Finasteride-Treatment-and\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Saturable Binding of Finasteride to Steroid 5α-reductase as ...\",\"description\":\"Pharmacodynamic model analysis suggested that the 5αR1 inhibition is dose-dependent in the dose range from 0.2 to 100 mg, while the 5αR2 inhibition is almost ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1347436715300239\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"[PDF] PROPECIA® (finasteride) Tablets - accessdata.fda.gov\",\"description\":\"Mean terminal half-life is approximately 5-6 hours in men 18-60 years of age and 8 hours in men more than 70 years of age. TABLE 3. Mean (SD) Pharmacokinetic ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Clinical pharmacokinetics and pharmacodynamics of finasteride\",\"description\":\"Finasteride is a potent 5 alpha-reductase inhibitor that has shown limited success in men treated for benign prostatic hyperplasia.Missing:  mechanism | Show results with:mechanism\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8846625/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Finasteride: Uses, Interactions, Mechanism of Action - DrugBank\",\"description\":\"In healthy subjects, about 32-46% of total oral dose of finasteride was excreted in the urine in the form of metabolites while about 51-64% of the dose was ...\",\"url\":\"https://go.drugbank.com/drugs/DB01216\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"[PDF] PROSCAR® - accessdata.fda.gov\",\"description\":\"The mean terminal half-life of finasteride in subjects ≥70 years of age was approximately 8 hours. (range, 6-15 hours; n=12), compared with 6 hours (range ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s033lbl.pdf\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"[PDF] PROPECIA® - accessdata.fda.gov\",\"description\":\"Mean terminal half-life in plasma was 4.5 hours. (range, 3.3-13.4 hours; n=12). Following an oral dose of 14C-finasteride in man (n=6), a mean of 39%. (range, ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"The Effect of Finasteride in Men with Benign Prostatic Hyperplasia\",\"description\":\"Oct 22, 1992 · The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJM199210223271701\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Propecia, Proscar (finasteride) dosing, indications, interactions ...\",\"description\":\"... 5-alpha reductase inhibitors (5-ARIs); The 2 trials are the Prostate Cancer ... Finasteride is a Type II 5α-reductase inhibitor that prevents conversion ...\u003c|separator|\u003e\",\"url\":\"https://reference.medscape.com/drug/propecia-proscar-finasteride-342824\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Finasteride (oral route) - Side effects \u0026 dosage - Mayo Clinic\",\"description\":\"Apr 1, 2025 · It will increase testosterone levels in the body, which decreases prostate size. The effect of finasteride will only last as long as the ...Missing:  tissue | Show results with:tissue\",\"url\":\"https://www.mayoclinic.org/drugs-supplements/finasteride-oral-route/description/drg-20063819\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"The Effect of Finasteride on the Risk of Acute Urinary Retention and ...\",\"description\":\"Feb 26, 1998 · Treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the probability of surgery and ...Study Design · Symptoms, Prostate Volume... · Discussion\u003c|separator|\u003e\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJM199802263380901\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"The Long-Term Effect of Doxazosin, Finasteride, and Combination ...\",\"description\":\"Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa030656\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"[PDF] Combination Alpha-Blocker and Finasteride Therapy for BPH ...\",\"description\":\"This study compared monotherapy with an alpha-blocker (doxazosin, titrated to a maximum of 8mg/day), a 5α-reductase inhibitor (finasteride, 5mg/day), or placebo ...\",\"url\":\"https://www.va.gov/formularyadvisor/DOC_PDF/Alpha_Blocker_and_Finasteride_Combination_Therapy_for_BPH.pdf\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Benign Prostatic Hyperplasia (BPH) Guideline\",\"description\":\"The goal of this revised guideline is to provide a useful reference on the effective evidence-based surgical management of male lower urinary tract symptoms ...\",\"url\":\"https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-%28bph%29-guideline\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Finasteride: Uses, Dosage, Side Effects, Warnings - Drugs.com\",\"description\":\"Jun 5, 2024 · Propecia (finasteride 1 mg tablets) became FDA-approved for male pattern hair loss (androgenetic alopecia) in men on December 19, 1997.Finasteride Dosage · Finasteride Interactions · Finasteride Reviews \u0026 Ratings\",\"url\":\"https://www.drugs.com/finasteride.html\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Finasteride in the treatment of men with androgenetic alopecia ...\",\"description\":\"Finasteride, an inhibitor of type II 5alpha-reductase, decreases serum and scalp DHT by inhibiting conversion of testosterone to DHT. Objective: Our purpose ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9777765/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Treatment Options for Androgenic Alopecia - U.S. Pharmacist\",\"description\":\"Aug 19, 2008 · Finasteride 1 mg has been found to reduce DHT levels in the scalp by over 60%.5. Clinical trials have proven the efficacy of finasteride.\",\"url\":\"https://www.uspharmacist.com/article/treatment-options-for-androgenic-alopecia-10959\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Guidelines on the use of finasteride in androgenetic alopecia\",\"description\":\"Finasteride is effective in the management of androgenetic alopecia. The mechanism of action and efficacy of this drug are proven. Several studies have shown ...\",\"url\":\"https://ijdvl.com/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia/\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Female-pattern hair loss: therapeutic update - ScienceDirect.com\",\"description\":\"Its use in women is off-label and it should be used with caution in women of childbearing age due to its teratogenic potential (feminization of the male fetus).\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0365059623000533\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Finasteride for women: Can it be used to treat hair loss? - Miiskin\",\"description\":\"Finasteride is teratogenic, which means it can cause feminization of a male fetus if a woman is exposed to it during pregnancy. Can topical finasteride be used ...Oral Spironolactone · Oral Minoxidil · Topical Minoxidil\",\"url\":\"https://miiskin.com/hair-loss/medications-for-hair-loss/finasteride-for-women/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Finasteride and Its Potential for the Treatment of Female Pattern Hair ...\",\"description\":\"This review summarizes the pharmacology and presents potential uses of finasteride in women, especially in the postmenopausal-aged group.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Safety of Antiandrogens for the Treatment of Female Androgenetic ...\",\"description\":\"May 23, 2024 · ... finasteride is also used to treat androgenetic alopecia in men. Its use in women is less common because of limited efficacy [47]. Although ...\",\"url\":\"https://www.mdpi.com/2077-0383/13/11/3052\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Comparison of finasteride versus flutamide in the ... - PubMed\",\"description\":\"Finasteride reduced the Ferriman-Gallwey score by 31.4% in the PCOS cases and by 34.2% in the idiopathic hirsutism cases, and hair diameter by 27.0-34.1% in ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10526249/\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Intermittent low-dose finasteride is as effective as daily ...\",\"description\":\"Finasteride at dosages ranging from 5–2.5 mg/day has been shown to be effective in decreasing hirsutism symptoms in women with polycystic ovary syndrome (PCOS) ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0015028204009240\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Comparison of Spironolactone, Flutamide, and Finasteride Efficacy ...\",\"description\":\"The present controlled trial demonstrates that spironolactone, flutamide, and finasteride are effective in the treatment of hirsutism, supporting conclusions of ...\",\"url\":\"https://academic.oup.com/jcem/article/85/1/89/2852067\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"[PDF] Systematic review of finasteride effect in women with hirsutism\",\"description\":\"The two studies in which finasteride was compared with placebo showed that hirsutism improved with finasteride8,9, especially after six months of treatment. No ...\",\"url\":\"https://www.scielo.br/j/ramb/a/kCLg7GYPJtpmGRwfFkB4yJG/?format=pdf\u0026lang=en\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"The efficacy and use of finasteride in women: a systematic review\",\"description\":\"Overall, doses of oral finasteride ranged from 0.5 to 5 mg/day, in females aged 6-88, over a duration of 6-12 months (57.6%), as monotherapy (88.9%), and for ...Missing:  safety | Show results with:safety\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/30604525/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Finasteride Treatment of Female Pattern Hair Loss - JAMA Network\",\"description\":\"Conclusions Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral ...\",\"url\":\"https://jamanetwork.com/journals/jamadermatology/fullarticle/403800\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"The safety and efficacy of finasteride for transgender men ... - PubMed\",\"description\":\"Sep 29, 2025 · Conclusion: Finasteride appears to be a safe and effective treatment for androgenetic alopecia in transgender men undergoing testosterone ...Missing:  off- label acne seborrhea evidence\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/41024043/\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"The safety and efficacy of finasteride for transgender men with ... - NIH\",\"description\":\"Sep 29, 2025 · A prospective study involving more than 3000 Japanese men with AGA demonstrated an efficacy rate of 87% for a 1-mg daily dose of finasteride, ...Missing:  acne | Show results with:acne\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12482827/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Finasteride Use During Pregnancy - Drugs.com\",\"description\":\"Risk summary: Based on the mechanism of action and findings in animals, this drug may cause abnormal development of external genitalia in a male fetus when ...\",\"url\":\"https://www.drugs.com/pregnancy/finasteride.html\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Finasteride use during pregnancy and early neonatal outcome\",\"description\":\"The use of antiandrogen drugs such as finasteride during pregnancy may carry the risk of birth defects, especially hypospadias.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/29855987/\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"FDA alerts health care providers, compounders and consumers\",\"description\":\"Apr 22, 2025 · Approved finasteride products are contraindicated in pregnancy because of the potential to cause abnormalities of a male fetus in a pregnant ...\",\"url\":\"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"The Influence of Finasteride on the Development of Prostate Cancer\",\"description\":\"Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa030660\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Prostate volume predicts outcome of treatment of benign ... - PubMed\",\"description\":\"Conclusions: This meta-analysis suggests that finasteride is most effective in men with large prostates. Men with small prostates may not be suitable candidates ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8804493/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Finasteride for benign prostatic hyperplasia - PMC - PubMed Central\",\"description\":\"Subgroup analysis: prostate size (\u003c 40 cc versus ≥ 40 cc). BPH progression (≥ 4 points). Follow‐up ≥ 1 year. (1 trial). For men with small prostates and ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8908761/\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Data From the MTOPS Trial | Journal of Urology\",\"description\":\"Apr 1, 2011 · Approximately 50% of patients had a baseline prostate volume of 30 ml or greater. The present analysis was based on the finasteride alone and ...\",\"url\":\"https://www.auajournals.org/doi/10.1016/j.juro.2010.11.060\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"[PDF] Propecia™ (finasteride) Tablet, 1 mg. - accessdata.fda.gov\",\"description\":\"Apr 13, 2011 · In a combined analysis of the two studies on vertex baldness, mean hair count changes from baseline were 91 vs -19 hairs (PROPECIA vs ...Missing:  pivotal | Show results with:pivotal\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Long-term (5-year) multinational experience with finasteride 1 mg in ...\",\"description\":\"Results: Treatment with finasteride led to durable improvements in scalp hair over five years (p 3/4 0.001 versus placebo, all endpoints), while treatment with ...Missing:  pivotal | Show results with:pivotal\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/11809594/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"The effectiveness of treatments for androgenetic alopecia - PubMed\",\"description\":\"Apr 7, 2017 · This meta-analysis strongly suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growth in men with ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/28396101/\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Efficacy of Finasteride in Female Pattern Hair Loss: A Meta-Analysis\",\"description\":\"In this study, we aimed to evaluate the efficacy of oral finasteride treatment for female patients with FPHL by performing a meta-analysis. We conducted ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8137337/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"results of a four-year, randomized trial comparing finasteride versus ...\",\"description\":\"Baseline PSA levels of 1.4 ng/mL or greater and enlarged prostate glands predict the best long-term response to finasteride compared with placebo.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10510925/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Benign prostatic hyperplasia as a progressive disease: a guide to ...\",\"description\":\"May 8, 2008 · In the PLESS study, after 4 years finasteride reduced the relative risk of AUR by 57% (7% of men receiving placebo and 3% of those receiving ...\u003c|separator|\u003e\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2008.01785.x\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Long-term (10-year) efficacy of finasteride in 523 Japanese men ...\",\"description\":\"Sep 19, 2019 · Long-term (10-year) treatment with 1 mg/day finasteride in Japanese men with androgenetic alopecia showed high efficacy in subjective and objective evaluations.Introduction · Methods · Results · DiscussionMissing:  extension | Show results with:extension\",\"url\":\"https://www.oatext.com/Long-term-%2810-year%29-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Androgenetic Alopecia Treatment \u0026 Management\",\"description\":\"Mar 25, 2024 · Finasteride must be continued indefinitely because discontinuation results in gradual progression of the disorder. A study in postmenopausal ...\",\"url\":\"https://emedicine.medscape.com/article/1070167-treatment\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Use of Finasteride in the Treatment of Men With Androgenetic ...\",\"description\":\"Median serum DHT levels decreased 71% and 72%, respectively, compared to a 1% increase with placebo. This study also demonstrated that at doses as low as 0.05 ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0022202X15529357\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Finasteride and High-Grade Prostate Cancer in ... - Oxford Academic\",\"description\":\"Sep 19, 2007 · The PCPT found a 24.8% reduction in the 7-year period prevalence of prostate cancer, i.e., the cumulative number of prostate cancers identified ...\",\"url\":\"https://academic.oup.com/jnci/article/99/18/1375/923438\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer\",\"description\":\"Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25%, but with an apparent increased risk ...\",\"url\":\"https://aacrjournals.org/cancerpreventionresearch/article/1/3/174/46398/Finasteride-Does-Not-Increase-the-Risk-of-High\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Finasteride and Erectile Dysfunction in Patients with Benign ...\",\"description\":\"Because, DHT has higher affinity for the androgen receptors and more effective at increasing nitric oxide (NO) synthase expression than total testosterone [18, ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6479090/\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Adverse Sexual Effects of Treatment with Finasteride or Dutasteride ...\",\"description\":\"Jan 1, 2019 · This systematic review and meta-analysis investigated the risk of adverse sexual effects due to treatment of androgenetic alopecia in male patients.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/30206635/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Signal detection between 5-alpha reductase inhibitors and the risk ...\",\"description\":\"Results: A total of 395 and 1299 reports of suicidality and depression, respectively, were identified in signal detection with finasteride and dutasteride.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40473994/\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase ...\",\"description\":\"Jun 25, 2025 · Suicidal ideation may arise from mood changes induced by finasteride, with evidence suggesting a possible genetic link between 5α-reductase ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12300150/\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase ...\",\"description\":\"Reduced levels of allopregnanolone due to finasteride use have been shown to impair GABAergic signaling, thereby reducing neuronal inhibition and ...\",\"url\":\"https://www.mdpi.com/1424-8247/18/7/957\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Measures to minimise risk of suicidal thoughts with finasteride and ...\",\"description\":\"May 8, 2025 · EMA's safety committee, PRAC, has confirmed suicidal ideation (suicidal thoughts) as a side effect of finasteride 1 and 5 mg tablets.\",\"url\":\"https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"EMA Decision Is In: Finasteride Linked to Suicidal Ideation - Medscape\",\"description\":\"May 9, 2025 · The EMA said that most cases of suicidal ideation were reported in people using 1 mg finasteride to treat male hair loss, and patients should be ...\",\"url\":\"https://www.medscape.com/viewarticle/ema-decision-finasteride-linked-suicidal-ideation-2025a1000b9x\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"EU drugs regulator confirms suicidal thoughts as side effect of hair ...\",\"description\":\"May 8, 2025 · Most cases of suicidal thoughts were reported in people using 1 milligram (mg) finasteride tablets, which are used to treat androgenetic ...\",\"url\":\"https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Suicidality, depression, anxiety higher in younger patients ... - Healio\",\"description\":\"Dec 3, 2020 · Finasteride, a 5-alpha-reductase inhibitor, has been linked to depression and anxiety, and reports of suicidality and psychological adverse ...\",\"url\":\"https://www.healio.com/news/dermatology/20201203/suicidality-depression-anxiety-higher-in-younger-patients-on-finasteride-for-alopecia\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Young Men Using Finasteride for Alopecia May Be More Suicide ...\",\"description\":\"Nov 12, 2020 · Men 45 years old and younger who use finasteride for hair loss are three times more likely to experience suicidal ideation, plan their suicide or attempt ...\",\"url\":\"https://www.pfsfoundation.org/news/young-men-using-finasteride-for-alopecia-may-be-more-suicide-prone-than-the-general-population-says-new-pharmacovigilance-research/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Suicidality and Psychological Adverse Events in Patients Treated ...\",\"description\":\"Nov 11, 2020 · At the population level, studies have found an increased risk of depression associated with finasteride use among patients with BPH.\",\"url\":\"https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Analysis of Data From Breast Diseases Treated With 5-Alpha ...\",\"description\":\"In total, 14 studies were included in the meta-analysis. Gynecomastia was significantly more common with 5ARIs treatment when compared with placebo (3.30% vs.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1526820918308371\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Persistent Gynecomastia due to Short-term Low-dose Finasteride for ...\",\"description\":\"Apr 24, 2024 · A comprehensive meta-analysis of studies of BPH treatment with high-dose finasteride demonstrated a 2-fold greater risk of gynecomastia in ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11040274/\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Finasteride: potential risk of male breast cancer - GOV.UK\",\"description\":\"Dec 11, 2014 · Up to November 2009, 50 cases of male breast cancer have been reported worldwide with 5 mg finasteride and three cases with the 1 mg dose.\u003c|separator|\u003e\",\"url\":\"https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancer\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Finasteride treatment and male breast cancer: a register‐based ...\",\"description\":\"Dec 13, 2017 · In this population‐based register study, we found a statistically significant 44% increased risk of MBC among men having finasteride prescribed ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5773955/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Finasteride Use and Risk of Male Breast Cancer: A Case–Control ...\",\"description\":\"This large confounder-adjusted study supports the view that exposure to finasteride is not associated materially with male breast cancer risk.\",\"url\":\"https://aacrjournals.org/cebp/article/28/5/980/71689/Finasteride-Use-and-Risk-of-Male-Breast-Cancer-A\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Long-term effects of finasteride on prostate specific antigen levels\",\"description\":\"Studies have shown that finasteride decreases prostate specific antigen (PSA) by approximately 50% during the first 12 months of use.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/16093979/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate ...\",\"description\":\"Aug 16, 2006 · Second, finasteride may improve the performance of PSA screening in the general population. Clinically, if finasteride does not reduce PSA by at ...Abstract · UBJECTS AND M ETHODS · ESULTS\",\"url\":\"https://academic.oup.com/jnci/article/98/16/1128/2521721\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Health Risks Associated with Long-Term Finasteride and ...\",\"description\":\"We suggest that long-term use of finasteride and dutasteride may be associated with health risks including NAFLD, IR, T2DM, dry eye disease and potential ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7308241/\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Maculopapular Drug Eruption Caused by Finasteride: A Case Report\",\"description\":\"Nov 17, 2023 · A 76-year-old male developed a maculopapular rash on his trunk and extremities. The rash appeared 2 months after Finasteride administration for his prostatic ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Post-finasteride syndrome - PMC - PubMed Central\",\"description\":\"Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term ...Missing:  efficacy | Show results with:efficacy\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Persistent sexual side effects of finasteride for male pattern hair loss\",\"description\":\"Results: Subjects reported new-onset persistent sexual dysfunction associated with the use of finasteride: 94% developed low libido, 92% developed erectile ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/21418145/\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"PFS by the Numbers - The Post-Finasteride Syndrome Foundation\",\"description\":\"Adverse drug reaction reports worldwide: 25,816. The World Health Organization Programme for International Drug Monitoring's database of adverse drug reactions ...Missing:  self- | Show results with:self-\",\"url\":\"https://www.pfsfoundation.org/pfs-by-the-numbers/\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Persistent sexual side effects of finasteride: could they be permanent?\",\"description\":\"In most men who developed persistent sexual side effects (≥3 months) despite the discontinuation of finasteride, the sexual dysfunction continued for many ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22789024/\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Characteristics of Men Who Report Persistent Sexual Symptoms ...\",\"description\":\"Furthermore, because men seeking treatment for alopecia have higher prevalence ... This work was supported in part by the Post-Finasteride Syndrome Foundation ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5155688/\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Preclinical Findings in a Post-Finasteride Rat Model - MDPI\",\"description\":\"Finasteride Withdrawal Decreases Acetate and Butyrate Fecal Levels and Induces Hypothalamic Neuroinflammation—Protective Effects of Allopregnanolone Treatment.2. Materials And Methods · 3. Results · 4. Discussion\",\"url\":\"https://www.mdpi.com/2218-273X/15/7/1044\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Gut Inflammation Induced by Finasteride Withdrawal - PubMed\",\"description\":\"Oct 26, 2022 · The obtained data demonstrate that the levels of allopregnanolone (ALLO) decreased after finasteride treatment and after its withdrawal.Missing:  studies | Show results with:studies\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36358917/\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Epigenetic Effects of Finasteride on Dopaminergic Signaling Pathways\",\"description\":\"May 21, 2024 · To evaluate the epigenetic effects of finasteride on dopaminergic signaling pathways, we treated human Leydig cells with finasteride and ...\",\"url\":\"https://journals.physiology.org/doi/abs/10.1152/physiol.2024.39.S1.1269\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Differential Gene Expression in Post-Finasteride Syndrome Patients\",\"description\":\"Aug 6, 2025 · Conclusion This study is the first to consider and demonstrate gene expression differences in patients with PFS as a potential etiology of ...\u003c|separator|\u003e\",\"url\":\"https://www.researchgate.net/publication/353127752_Differential_Gene_Expression_in_Post-Finasteride_Syndrome_Patients\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Finasteride-Induced Suicides up 8.4% in WHO's VigiBase\",\"description\":\"Also in the category of Suicidal and Self-Injurious Behavior, finasteride-induced suicidal ideation rose 4.2%, while suicide attempts rose 3.7%. Overall, ...Missing:  spike | Show results with:spike\",\"url\":\"https://www.pfsfoundation.org/news/finasteride-induced-suicides-up-8-4-in-whos-vigibase/\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Multidimensional assessment of adverse events of finasteride\",\"description\":\"Common AEs in all age groups included erectile dysfunction, decreased libido, depression, suicidal ideation, psychotic disturbances and attention disorders.\",\"url\":\"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309849\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Characteristics of Men Who Report Persistent Sexual Symptoms ...\",\"description\":\"Sep 23, 2024 · fMRI findings in a cohort of post-finasteride patients without pre-existing depression revealed abnormal function in brain areas linked to ...\u003c|separator|\u003e\",\"url\":\"https://www.pfsnetwork.org/science/y77lkfbdtqfnn42n5n9cvjzdqmsjd1-IZCIP\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length ...\",\"description\":\"Dec 23, 2016 · ... polymorphisms in the androgen receptor (AR) gene are implicated in PFS. Methods. AR polymorphisms were studied according to PFS symptoms in ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5302381/\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"\",\"description\":\"\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70243\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"[PDF] Docket No. FDA-2017-P-5787 - Public Citizen\",\"description\":\"Jun 8, 2022 · Based on our review of these materials and for the reasons described below, the Petition is denied in part and granted in part. I. FINASTERIDE ( ...Missing:  rejection | Show results with:rejection\",\"url\":\"https://www.citizen.org/wp-content/uploads/Response-to-PFSF-CP-FDA-2017-P-5787-002.pdf\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Concerns Over Compounded Topical Finasteride Prompt FDA Alert\",\"description\":\"Apr 28, 2025 · Between 2019 and 2024, 32 cases of adverse events linked to compounded topical finasteride were reported to the FDA Adverse Event Reporting ...Missing:  ADRs | Show results with:ADRs\",\"url\":\"https://www.dermatologyadvisor.com/news/concerns-over-compounded-topical-finasteride-prompt-fda-alert/\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Meeting highlights from the Pharmacovigilance Risk Assessment ...\",\"description\":\"May 8, 2025 · EMA's safety committee (PRAC) has confirmed suicidal ideation (suicidal thoughts) as a side effect of finasteride 1 and 5 mg tablets.\",\"url\":\"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-may-2025\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Propecia Lawsuits - Sexual Dysfunction Claims \u0026 Litigation History\",\"description\":\"Men who suffered from sexual dysfunction or other side effects after taking Propecia have sued the drug's maker, Merck \u0026 Co.Status of Lawsuits · Lawsuit History · Lawsuit Claims\",\"url\":\"https://www.drugwatch.com/propecia/lawsuits/\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"'Hundreds to Thousands' of Men Might Have Died by Suicide Due to ...\",\"description\":\"Sep 26, 2025 · Testimony prompted first known systematic review of evidence supporting a causal link between finasteride 1 mg and neuropsychiatric reactions.\",\"url\":\"https://www.pfsfoundation.org/news/hundreds-to-thousands-of-men-might-have-died-by-suicide-due-to-pfs-reasons-expert-witness-in-propecia-litigation-2/\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"FDA Sued Over Inaction on Dangerous Hair Loss Medication Propecia\",\"description\":\"Sep 8, 2021 · The lawsuit filed today claims that FDA has acted unlawfully in failing to act on PFSF's petition. Long-term use of Propecia can lead to post- ...\",\"url\":\"https://www.citizen.org/news/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia/\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Clinical dose ranging studies with finasteride, a type 2 ... - PubMed\",\"description\":\"Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10495375/\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Sexual, physical, and overall adverse effects in patients treated with ...\",\"description\":\"The use of 5ARIs carried a 1.57-fold risk of sexual dysfunction (95% CI: 1.19–2.08). In the subgroup analysis, the RR was 1.66 (95% CI: 1.20–2.30) for 1 mg day− ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9295476/\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"a study of the clinical characteristics and genetic variants ... - PubMed\",\"description\":\"With research progress, genetic screening may be a promising way to avoid the harmful effects of finasteride in people with related genetic risk factors.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36386264/\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Efficacy and safety of topical finasteride spray solution for male ... - NIH\",\"description\":\"Oral finasteride is a well‐established treatment for men with androgenetic alopecia (AGA), but long‐term therapy is not always acceptable to patients.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Literature Review: Topical Finasteride: To Use or Not to Use?\",\"description\":\"They found that the DHT was reduced by 68-75% with topical finasteride and by 62-72% with oral finasteride. There were no relevant changes in plasma ...\",\"url\":\"https://www.ishrs-htforum.org/content/28/3/112\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Does Topical Finasteride Work? - Perfect Hair Health\",\"description\":\"Jul 29, 2025 · Systemic finasteride (oral) reduced mean serum DHT by 55.6%, whereas topical finasteride reduced it by 34.5%. Plasma finasteride exposure from ...\",\"url\":\"https://perfecthairhealth.com/does-topical-finasteride-work/\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Efficacy and safety of topical finasteride spray solution for male ...\",\"description\":\"Its effect is similar to that of oral finasteride, but with markedly lower systemic exposure and less impact on serum DHT concentrations.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34634163/\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"\",\"description\":\"\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/ijd.17957\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Compounded Topical Finasteride Products Associated With Serious ...\",\"description\":\"Jul 1, 2025 · Compounded topical finasteride products have been associated with serious potential risks, warns Food and Drug Administration (FDA) in a news release.Missing:  ADRs | Show results with:ADRs\",\"url\":\"https://nabp.pharmacy/news/blog/regulatory_news/compounded-topical-finasteride-products-associated-with-serious-risks/\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"[PDF] COMPARATIVE ANALYSIS OF TOPICAL AND ORAL FINASTERIDE ...\",\"description\":\"May 12, 2025 · While, topical formulations provide a safer profile with suggestively lower systemic absorption and adverse effects, oral finasteride may.\",\"url\":\"https://www.ijbamr.com/assets/images/issues/pdf/71nag2_6w0c1i_34kUVI_YI8x3j_177107.pdf\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Is the Safety of Finasteride Correlated With Its Route of Administration\",\"description\":\"Jul 15, 2025 · Results: Fewer signals for PFS-like AEs were detected with topical finasteride compared to oral finasteride in both eras.Missing:  avoidance | Show results with:avoidance\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40662444/\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Study Used to Push Non-FDA-Approved Topical Finasteride ...\",\"description\":\"Mar 20, 2023 · Last month we revealed that, to date, 12 PFS patients have filed case reports with us indicating that they developed the condition after using ...Missing:  avoidance | Show results with:avoidance\",\"url\":\"https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"\",\"description\":\"\",\"url\":\"https://hcplive.com/view/study-compares-safety-findings-oral-versus-topical-finasteride-for-alopecia\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Testosterone replacement in the setting of Finasteride therapy\",\"description\":\"Testosterone replacement can be safely prescribed alongside finasteride in patients with low testosterone (predominantly for general well being and bone ...\",\"url\":\"https://www.endocrine-abstracts.org/ea/0021/ea0021p43\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"PSA adjustments are required in men taking 5-ARIs - Urology Times\",\"description\":\"Jul 3, 2019 · When using 5-ARIs (finasteride, dutasteride), the observed PSA level should be adjusted (by a factor of 2) to obtain the representative PSA level.\",\"url\":\"https://www.urologytimes.com/view/psa-adjustments-are-required-men-taking-5-aris\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"U.S. court let Merck hide secrets about popular drug's risks - Reuters\",\"description\":\"Sep 11, 2019 · Merck initially obtained FDA approval in 1992 to market finasteride in a five-milligram pill called Proscar to treat enlarged prostate.\",\"url\":\"https://www.reuters.com/investigates/special-report/usa-courts-secrecy-propecia/\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Finasteride, a Type 2 5alpha-reductase inhibitor, in the ... - PubMed\",\"description\":\"Moreover, Type 2 5alpha-reductase has been detected in scalp hair follicles, and balding scalps contain increased Type 2 5alpha-reductase activity and DHT ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/15992088/\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"MERCK's PROSCAR (FINASTERIDE) APPROVED JUNE 19 AFTER ...\",\"description\":\"Jun 22, 1992 · Merck's benign prostatic hyperplasia treatment Proscar (finasteride) was approved by FDA June 19 after a 14-month agency review.\",\"url\":\"https://insights.citeline.com/PS021070/MERCKs-PROSCAR-FINASTERIDE-APPROVED-JUNE-19-AFTER-14MONTH-REVIEW/\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"[PDF] finasteride: List of nationally authorised medicinal products PSUSA ...\",\"description\":\"Apr 11, 2019 · Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us ... PROSCAR, 5 mg, tabletki powlekane not available. R/3621. MSD ...\",\"url\":\"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"FDA Warns of Topical Finasteride Risks - Conexiant\",\"description\":\"Apr 24, 2025 · ... FDA approval for these formulations. While two oral finasteride products—Proscar (approved June 19, 1992) and Propecia (approved December 19 ...\",\"url\":\"https://conexiant.com/dermatology/articles/fda-warns-of-topical-finasteride-risks/\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"\",\"description\":\"\",\"url\":\"https://upguys.com/blog/finasteride-mechanism-of-action\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Regulation overview - Finasteride Watch\",\"description\":\"1998–99: Finasteride (1 mg) approved in numerous countries in Europe, South ... Approval date. Argentina, 27-Feb-1998. Aruba, 23-Feb-2000. Australia, 26-Jun ...\",\"url\":\"https://finasterideinfo.org/regulation/\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Effect of finasteride on serum PSA concentration in men with benign ...\",\"description\":\"This article describes the effect of finasteride on the serum PSA concentration in the North American Phase III clinical trial and discusses implications of ...Missing:  1990s | Show results with:1990s\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/7505970/\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Long-Term Survival of Participants in the Prostate Cancer ...\",\"description\":\"Aug 15, 2013 · In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the relative risk of prostate cancer by 24.8% (with 803 cancers in 4368 men ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa1215932\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Finasteride in the treatment of men with androgenetic alopecia\",\"description\":\"Conclusion: In men with male pattern hair loss, finasteride 1 mg/d slowed the progression of hair loss and increased hair growth in clinical trials over 2 years ...\u003c|separator|\u003e\",\"url\":\"https://www.jaad.org/article/S0190-9622%2898%2970007-6/abstract\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"[PDF] 1 This label may not be the latest approved by FDA. For current ...\",\"description\":\"The incidence of Gleason score 8-10 prostate cancer was higher in men treated with finasteride (1.8%) than in those treated with placebo (1.1%) [see Indications ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s048lbl.pdf\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic ...\",\"description\":\"Finasteride induced a decrease of prostate volume by 30%. When prostate volume decreases and tumor volume remains the same, the relative tumor volume should ...\",\"url\":\"https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961690-X/fulltext\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Finasteride and high-grade prostate cancer in the ... - PubMed\",\"description\":\"Sep 19, 2007 · Background: The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/17848673/\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Finasteride in the treatment of hirsutism: new therapeutic perspectives\",\"description\":\"Finasteride is very effective and well tolerated in the treatment of both idiopathic hirsutism and of hirsutism in patients with PCOS.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0015028216583885\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Finasteride (Propecia, Proscar) - Uses, Side Effects, and More\",\"description\":\"Sep 24, 2024 · Itching, skin rash, or pale red bumps on the skin called hives; Nausea or vomiting; Dizziness, feeling lightheaded or fainting; Stomach cramps ...Missing:  dermatological urticaria\",\"url\":\"https://www.webmd.com/drugs/2/drug-1548-167/finasteride-oral/finasteride-oral/details\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Generic Propecia Availability - Drugs.com\",\"description\":\"Oct 8, 2025 · Manufacturer: ACCORD HLTHCARE Approval date: November 5, 2013 · Manufacturer: ALKEM LABS LTD Approval date: January 6, 2017 · Manufacturer: ...\",\"url\":\"https://www.drugs.com/availability/generic-propecia.html\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.drugpatentwatch.com/p/generic-api/FINASTERIDE\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.drugpatentwatch.com/p/drug-price/drugname/FINASTERIDE\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.doctorfox.co.uk/news/patent-for-propecia-expires-in-the-uk/\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.goodrx.com/finasteride\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"How to Get Finasteride: Is It Over the Counter? | Good Health by Hims\",\"description\":\"Finasteride is not available over the counter in the US. It's only available with a prescription. However, it can be very easy and inexpensive to get a ...Missing:  attempts | Show results with:attempts\",\"url\":\"https://www.hims.com/blog/is-finasteride-over-the-counter\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Finasteride- and dutasteride-containing medicinal products - referral\",\"description\":\"On 19 June 2025, the CMDh1 endorsed measures recommended by EMA's safety committee, PRAC, to minimise the risk of suicidal ideation (suicidal thoughts) with ...Overview · Key facts · All documents\",\"url\":\"https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Finasteride Market Size \u0026 Share | Growth Report 2026-2035\",\"description\":\"Sep 9, 2025 · Finasteride Market size was valued at approximately USD 1.6 billion in 2025 and is projected to reach around USD 4.6 billion by the end of 2035, ...\",\"url\":\"https://www.researchnester.com/reports/finasteride-market/2984\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"[PDF] the 2005 prohibited list international standard - WADA\",\"description\":\"Sep 23, 2004 · THE 2005 PROHIBITED LIST ... Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders ...\",\"url\":\"https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2005_EN.pdf\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Investigation about the deffects and the detection of finasteride, a ...\",\"description\":\"The application of finasteride may prevent the detection of misuse of anabolic-androgenic steroids like nandrolone, norandrostendione, norandrostenediols, ...\",\"url\":\"https://www.wada-ama.org/en/resources/scientific-research/investigation-about-deffects-and-detection-finasteride-substance\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Doping-control analysis of the 5alpha-reductase inhibitor finasteride\",\"description\":\"5alpha-Reductase inhibitors such as finasteride are prohibited in sports according to the World Anti-Doping Agency. This class of drugs is used ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/17417080/\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"How Does WADA Decide What Drugs Are Banned? - VICE\",\"description\":\"Jul 13, 2017 · In 2005, WADA added finasteride to the banned list. Lund didn't check the list that year, so he didn't know it was banned, but he continued to ...\",\"url\":\"https://www.vice.com/en/article/how-does-wada-decide-what-drugs-are-banned/\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"5α-reductase inhibitors: Evaluation of their potential confounding ...\",\"description\":\"Our results confirmed the impact of finasteride, especially if chronically administered, on the enzymatic pathway of testosterone and nandrolone, and pointed ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34318592/\",\"favicon\":\"\"},{\"id\":\"150\",\"title\":\"Musculoskeletal and prostate effects of combined testosterone ... - NIH\",\"description\":\"We conclude that a higher-than-replacement TE combined with finasteride significantly increases muscle strength and BMD and reduces body fat without causing ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4073894/\",\"favicon\":\"\"},{\"id\":\"151\",\"title\":\"Therapeutic Use Exemptions (TUEs) | World Anti Doping Agency\",\"description\":\"Athletes do not apply to WADA for a TUE. Athletes should apply for a TUE as soon as possible after being prescribed the medical substance or route of ...International Standard · Guidelines for the International... · At-a-GlanceMissing:  finasteride | Show results with:finasteride\",\"url\":\"https://www.wada-ama.org/en/athletes-support-personnel/therapeutic-use-exemptions-tues\",\"favicon\":\"\"},{\"id\":\"152\",\"title\":\"Hair-loss drug wiped from doping banned list - ABC News\",\"description\":\"Oct 27, 2008 · Finasteride, usually prescribed to slow the process of hair loss, has been removed from WADA's 2009 banned list because scientists can now more easily detect ...\",\"url\":\"https://www.abc.net.au/news/2008-10-28/hair-loss-drug-wiped-from-doping-banned-list/184554\",\"favicon\":\"\"},{\"id\":\"153\",\"title\":\"The Prohibited List | World Anti Doping Agency - WADA\",\"description\":\"Jun 1, 2019 · The List of Prohibited Substances and Methods (List) indicates what substances and methods are prohibited in sport and when.Athletes \u0026 Support Personnel · Liste des interdictions · Footer\",\"url\":\"https://www.wada-ama.org/en/prohibited-list\",\"favicon\":\"\"},{\"id\":\"154\",\"title\":\"Why is there stigma around male baldness? - BBC\",\"description\":\"May 9, 2018 · Scientists say a drug normally prescribed for osteoporosis could potentially lead to a new treatment for hair loss. But why is there stigma ...\",\"url\":\"https://www.bbc.com/news/health-44052917\",\"favicon\":\"\"},{\"id\":\"155\",\"title\":\"Controversies in the treatment of androgenetic alopecia: The history ...\",\"description\":\"Sep 25, 2018 · Subsequently, scientists at Merck, Inc. developed a lower dosage oral finasteride for the treatment of AGA. In 1997, the U.S. FDA approved ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/dth.12647\",\"favicon\":\"\"},{\"id\":\"156\",\"title\":\"Hair loss drug finasteride can cause debilitating side-effects, men say\",\"description\":\"Mar 17, 2025 · A six-month investigation of the hair loss drug finasteride say it caused sexual, psychological and physical side-effects for them that have lasted months if ...Missing:  perception | Show results with:perception\",\"url\":\"https://www.cbc.ca/news/health/hair-loss-drug-finasteride-side-effects-1.7483898\",\"favicon\":\"\"},{\"id\":\"157\",\"title\":\"Hair loss treatment used by millions linked to suicide risk\",\"description\":\"Oct 8, 2025 · New research suggests that patients using a popular drug for male pattern baldness face a significantly higher risk of mood disorders and ...\",\"url\":\"https://nypost.com/2025/10/08/health/hair-loss-treatment-used-by-millions-linked-to-suicide-risk/\",\"favicon\":\"\"},{\"id\":\"158\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.medicalbrief.co.za/fda-merck-accused-of-covering-up-hair-loss-pills-suicide-link/\",\"favicon\":\"\"},{\"id\":\"159\",\"title\":\"Risks of Topical Finasteride - Consumer Med Safety\",\"description\":\"Jul 16, 2025 · The FDA has not approved any form of topical finasteride. However, in the last 5 years, there have been 32 cases of harm reported to the FDA ...\u003c|separator|\u003e\",\"url\":\"https://www.consumermedsafety.org/safety-articles/risks-of-topical-finasteride\",\"favicon\":\"\"},{\"id\":\"160\",\"title\":\"[PDF] Finasteride-dutasteride Art 31 PhV - PRAC assessment report\",\"description\":\"May 8, 2025 · Finasteride- and dutasteride-containing medicinal products have a known risk of psychiatric disorders. In 2024, suicidal ideation was added to ...Missing:  lawsuits | Show results with:lawsuits\",\"url\":\"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf\",\"favicon\":\"\"},{\"id\":\"161\",\"title\":\"Finasteride ADRs Soar 10000% Week Over Week, Says World ...\",\"description\":\"Startling rise exceeds 2024 record by 42%—with 6 months still to go in 2025—and includes 119 new reports of suicidal ideation. May 17, 2025. Dear Friends:.\",\"url\":\"https://www.pfsfoundation.org/news/finasteride-adrs-soar-10000-week-over-week-says-world-health-organization/\",\"favicon\":\"\"},{\"id\":\"162\",\"title\":\"Popular hair-loss pill linked to depression and suicide | ScienceDaily\",\"description\":\"Oct 13, 2025 · The findings show a clear trend: people who used finasteride were far more likely to experience mood disorders and suicidal thoughts than those ...\",\"url\":\"https://www.sciencedaily.com/releases/2025/10/251013040343.htm\",\"favicon\":\"\"},{\"id\":\"163\",\"title\":\"Long-Term Effectiveness and Safety of Dutasteride versus ... - NIH\",\"description\":\"Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9561294/\",\"favicon\":\"\"},{\"id\":\"164\",\"title\":\"Efficacy and safety of twice- or thrice-weekly dutasteride versus daily ...\",\"description\":\"Sep 15, 2025 · Thrice-weekly dutasteride showed a greater moderate-to-marked improvement than once-daily finasteride (35% vs 21%). Sexual adverse events were ...\",\"url\":\"https://www.jaadinternational.org/article/S2666-3287%2825%2900101-4/fulltext\",\"favicon\":\"\"},{\"id\":\"165\",\"title\":\"Dutasteride vs. Finasteride | A thorough comparison [2025]\",\"description\":\"Apr 18, 2025 · While both belong to the same drug class with similar risks, they've demonstrated different levels of efficacy in clinical studies and generally sell at ...The comparison in a nutshell · What are dutasteride and... · Cost comparisons\",\"url\":\"https://www.innerbody.com/dutasteride-vs-finasteride\",\"favicon\":\"\"},{\"id\":\"166\",\"title\":\"a systematic review and meta-analysis of randomized controlled trials\",\"description\":\"Oct 7, 2025 · Combination therapy with topical finasteride and minoxidil has emerged as a promising strategy, potentially offering synergistic effects while ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12537375/\",\"favicon\":\"\"},{\"id\":\"167\",\"title\":\"Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus ...\",\"description\":\"Oct 22, 2024 · The combination of topical finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic alopecia compared to ...Missing:  emerging | Show results with:emerging\",\"url\":\"https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/\",\"favicon\":\"\"},{\"id\":\"168\",\"title\":\"Topical finasteride, minoxidil combination efficacious in male ...\",\"description\":\"Dec 8, 2024 · A combination of topical finasteride and minoxidil was more efficacious than minoxidil alone in the treatment of male pattern androgenic alopecia, according to ...Missing:  emerging | Show results with:emerging\",\"url\":\"https://www.healio.com/news/dermatology/20241205/topical-finasteride-minoxidil-combination-efficacious-in-male-androgenic-alopecia\",\"favicon\":\"\"},{\"id\":\"169\",\"title\":\"Systematic Review of Platelet-Rich Plasma Use in Androgenetic ...\",\"description\":\"It be may considered as a safe and effective alternative procedure to treat hair loss compared with Minoxidil and Finasteride.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7216252/\",\"favicon\":\"\"},{\"id\":\"170\",\"title\":\"PRP Vs Finasteride: Which One Is Better For You? (2024)\",\"description\":\"Mar 23, 2025 · While both PRP and finasteride effectively treat hair loss, research suggests PRP may be a better option. It delivers strong results with fewer ...What is PRP? · An effective alternative to PRP... · PRP vs finasteride: What are...\",\"url\":\"https://scandinavianbiolabs.com/blogs/hair-loss/prp-vs-finasteride\",\"favicon\":\"\"},{\"id\":\"171\",\"title\":\"A study to compare the efficacy and safety of platelet rich plasma ...\",\"description\":\"To the best of our knowledge, this was the first prospective study comparing the efficacy of PRP and minoxidil fortified with finasteride therapy for the ...\",\"url\":\"https://ijced.org/archive/volume/8/issue/2/article/7808\",\"favicon\":\"\"},{\"id\":\"172\",\"title\":\"Genetic variations associated with response to dutasteride in the ...\",\"description\":\"Sep 16, 2019 · We also found that response to dutasteride may be associated with variants of genes involved in steroid hormone metabolism, such as SRD5A1, ESR1 ...Missing:  screening | Show results with:screening\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6746394/\",\"favicon\":\"\"},{\"id\":\"173\",\"title\":\"SRD5A1 \u0026 2: Can They Predict Regrowth From 5AR Inhibitors?\",\"description\":\"Aug 6, 2024 · Genetic testing companies suggest certain SR5DA1 and 2 variants might predict how well someone responds to treatments like finasteride and dutasteride.Missing:  screening | Show results with:screening\",\"url\":\"https://perfecthairhealth.com/srd5a1-2-can-these-genes-predict-regrowth-from-5-alpha-reductase-inhibitors/\",\"favicon\":\"\"},{\"id\":\"174\",\"title\":\"Finasteride Response through the Genetic Tests - Dr. Alba Reyes\",\"description\":\"The Genetic Test for Finasteride Response test will predict if a patient will respond to the Finasteride treatment.Missing:  screening 5AR\",\"url\":\"https://www.albareyes.com/genetic-tests/genetic-tests-for-finasteride-response/\",\"favicon\":\"\"},{\"id\":\"175\",\"title\":\"Clinical Trials - The Post-Finasteride Syndrome Foundation\",\"description\":\"The PFS Foundation monitors FDA trials for products in clinical development that could potentially prove therapeutic for the condition.Missing:  emerging | Show results with:emerging\",\"url\":\"https://www.pfsfoundation.org/research/\",\"favicon\":\"\"},{\"id\":\"176\",\"title\":\"Case report: a study of the clinical characteristics and genetic ...\",\"description\":\"Some genes are abnormal in PFS patients, suggesting that clinical and genetic evaluation might be needed before the prescription of 5α-reductase inhibitors.Missing:  5AR | Show results with:5AR\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9641066/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"5faf8437be1b\",\"caption\":\"Finasteride chemical structure\",\"url\":\"./_assets_/Finasteride.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Finasteride\",\"title\":\"Finasteride\",\"content\":\"$1f\",\"description\":\"Finasteride\\n\\nFinasteride chemical structure \\nFinasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme...\",\"metadata\":{\"categories\":[\"Propecia\",\"Proscar\"],\"lastModified\":\"1761583517\",\"contentLength\":\"78127\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"381227\",\"recentViews\":\"381227\",\"dailyAvgViews\":12707.56640625,\"qualityScore\":1,\"lastViewed\":\"1761885328\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761885329129,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Finasteride\"],\"queryHash\":\"[\\\"page\\\",\\\"Finasteride\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Finasteride\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Propecia, Proscar\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Finasteride\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Finasteride\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Finasteride\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Finasteride\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.517Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Finasteride\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Finasteride is a synthetic 4-azasteroid compound that functions as a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By selectively reducing DHT levels in tissues such as the prostate and scalp, it treats symptoms of benign prostatic hyperplasia (BPH) by shrinking prostate volume and androgenetic alopecia by slowing hair follicle miniaturization in men. Developed...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Y2Y5ZTAzMWMtNzNlMS00NWVmLWJmZGQtYzhmMDEwMGU1MDE1">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Finasteride\"}]}]\n"])</script></body></html>